BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1693] [Article Influence: 164.2] [Reference Citation Analysis]
Number Citing Articles
1 Yamanishi K, Maeda S, Kuwahara-Otani S, Watanabe Y, Yoshida M, Ikubo K, Okuzaki D, El-Darawish Y, Li W, Nakasho K, Nojima H, Yamanishi H, Hayakawa T, Okamura H, Matsunaga H. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl Res. 2016;173:101-114.e7. [PMID: 27063959 DOI: 10.1016/j.trsl.2016.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
2 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 van Mierlo KM, Schaap FG, Dejong CH, Olde Damink SW. Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. J Hepatol. 2016;65:1217-1231. [PMID: 27312944 DOI: 10.1016/j.jhep.2016.06.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
4 Verderese JP, Younossi Z. Interaction of type 2 diabetes and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2013;7:405-7. [PMID: 23899279 DOI: 10.1586/17474124.2013.811047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wells MM, Li Z, Addeman B, McKenzie CA, Mujoomdar A, Beaton M, Bird J. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population.Can J Gastroenterol Hepatol. 2016;2016:4930987. [PMID: 27446844 DOI: 10.1155/2016/4930987] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
6 Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis on portal hypertension. PLoS One 2019;14:e0224506. [PMID: 31693695 DOI: 10.1371/journal.pone.0224506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Mohamed SM, Mohammed DS, Abd Elhaliem NG, Elbadry MI, Abu-dief EE. Mangosteen Can Improve Steatohepatitis through Modulating Inflammatory and Autophagy/Apoptosis Cell Injury: An Animal Model Study. Cytol Genet 2021;55:480-90. [DOI: 10.3103/s0095452721050091] [Reference Citation Analysis]
8 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. [PMID: 26090468 DOI: 10.1155/2015/979515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
10 Hu W, Shao X, Guo D, Hao H, Zhang Y, Xia M, Gong Y, Zhou H, Fan Y, Yu W. Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population. PLoS One 2017;12:e0170758. [PMID: 28125672 DOI: 10.1371/journal.pone.0170758] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chaim FDM, Pascoal LB, Chaim FHM, Palma BB, Damázio TA, da Costa LBE, Carvalho R, Cazzo E, Gestic MA, Utrini MP, Milanski M, Chaim EA, Leal RF. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep 2020;10:8496. [PMID: 32444690 DOI: 10.1038/s41598-020-65556-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770. [PMID: 28445310 DOI: 10.1097/md.0000000000006770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
13 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
14 Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. J Clin Med 2018;7:E562. [PMID: 30562976 DOI: 10.3390/jcm7120562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
15 Naveau S, Lamouri K, Pourcher G, Njiké-Nakseu M, Ferretti S, Courie R, Tranchart H, Ghinoiu M, Balian A, Prévot S. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 2014;24:1693-1701. [PMID: 24841950 DOI: 10.1007/s11695-014-1235-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
16 Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 2015;13:193. [PMID: 26077675 DOI: 10.1186/s12967-015-0552-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 10.3] [Reference Citation Analysis]
17 Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterol 2019;19:41. [PMID: 30885145 DOI: 10.1186/s12876-019-0958-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
18 Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol 2021;32:200-6. [PMID: 33883445 DOI: 10.1097/MOL.0000000000000756] [Reference Citation Analysis]
19 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. [PMID: 26707365 DOI: 10.1002/hep.28431] [Cited by in Crossref: 3251] [Cited by in F6Publishing: 3077] [Article Influence: 541.8] [Reference Citation Analysis]
20 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
22 Clark VC, Marek G, Liu C, Collinsworth A, Shuster J, Kurtz T, Nolte J, Brantly M. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. Journal of Hepatology 2018;69:1357-64. [DOI: 10.1016/j.jhep.2018.08.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
23 Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015;63:486-493. [PMID: 25772036 DOI: 10.1016/j.jhep.2015.02.051] [Cited by in Crossref: 162] [Cited by in F6Publishing: 153] [Article Influence: 23.1] [Reference Citation Analysis]
24 Soni NK, Nookaew I, Sandberg AS, Gabrielsson BG. Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice. Lipids Health Dis 2015;14:74. [PMID: 26193881 DOI: 10.1186/s12944-015-0072-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
25 Georgoulis M, Kontogianni MD, Tileli N, Margariti A, Fragopoulou E, Tiniakos D, Zafiropoulou R, Papatheodoridis G. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr 2014;53:1727-35. [DOI: 10.1007/s00394-014-0679-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
26 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Rabiee B, Roozafzai F, Hemasi GR, Poustchi H, Keyvani H, Khonsari MR, Ajdarkosh H, Maadi M, Sima Saeedian F, Zamani F. The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East J Dig Dis 2017;9:86-93. [PMID: 28638584 DOI: 10.15171/mejdd.2017.56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
28 Kawaguchi T, Nakano D, Oriishi T, Torimura T. Effects of isomaltulose on insulin resistance and metabolites in patients with non‑alcoholic fatty liver disease: A metabolomic analysis. Mol Med Rep 2018;18:2033-42. [PMID: 29956790 DOI: 10.3892/mmr.2018.9223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
30 Almahmoud MH, Al Khawaja NM, Alkinani A, Khader Y, Ajlouni KM. Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. Ann Med Surg (Lond) 2021;68:102677. [PMID: 34401141 DOI: 10.1016/j.amsu.2021.102677] [Reference Citation Analysis]
31 Kieffer DA, Piccolo BD, Marco ML, Kim EB, Goodson ML, Keenan MJ, Dunn TN, Knudsen KE, Adams SH, Martin RJ. Obese Mice Fed a Diet Supplemented with Enzyme-Treated Wheat Bran Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria. J Nutr 2016;146:2445-60. [PMID: 27798344 DOI: 10.3945/jn.116.238923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
32 Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am 2013;42:809-32. [PMID: 24286951 DOI: 10.1016/j.ecl.2013.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
33 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
34 Radmard AR, Poustchi H, Dadgostar M, Yoonessi A, Kooraki S, Jafari E, Hashemi Taheri AP, Malekzadeh R, Merat S. Liver enzyme levels and hepatic iron content in Fatty liver: a noninvasive assessment in general population by T2* mapping. Acad Radiol. 2015;22:714-721. [PMID: 25754799 DOI: 10.1016/j.acra.2015.01.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Nakamoto K, Shimada K, Harada S, Morimoto Y, Hirasawa A, Tokuyama S. DHA supplementation prevent the progression of NASH via GPR120 signaling. Eur J Pharmacol 2018;820:31-8. [PMID: 29221950 DOI: 10.1016/j.ejphar.2017.11.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
36 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open 2020;4:808-17. [PMID: 33102749 DOI: 10.1002/jgh3.12349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Maconi G, Furfaro F, Fries W, Dell'Era A, Bezzio C, Costantino G, Giuliano V, Alibrandi A, Guzowski T, Bassotti G. Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. Liver Int 2017;37:141-7. [PMID: 27375263 DOI: 10.1111/liv.13198] [Reference Citation Analysis]
39 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, D'Assante R, Zappulo E, Borgia G, Gentile I. The role of curcumin in liver diseases. Arch Med Sci 2019;15:1608-20. [PMID: 31749891 DOI: 10.5114/aoms.2018.73596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhou Y, Ding Y, Zhang J, Zhang P, Wang J, Li Z. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomedicine & Pharmacotherapy 2018;97:1397-408. [DOI: 10.1016/j.biopha.2017.10.035] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
42 Brady CW. Liver disease in menopause. World J Gastroenterol 2015; 21(25): 7613-7620 [PMID: 26167064 DOI: 10.3748/wjg.v21.i25.7613] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
43 Zeng X, Yang J, Hu O, Huang J, Ran L, Chen M, Zhang Y, Zhou X, Zhu J, Zhang Q, Yi L, Mi M. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. Antioxid Redox Signal. 2019;30:163-183. [PMID: 29310441 DOI: 10.1089/ars.2017.7172] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 13.3] [Reference Citation Analysis]
44 Kim BJ, Cheong ES, Kang JG, Kim BS, Kang JH. Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: From the CAESAR study. J Clin Lipidol. 2016;10:619-626.e1. [PMID: 27206950 DOI: 10.1016/j.jacl.2016.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
45 Cheng K, Jia P, Ji S, Song Z, Zhang H, Zhang L, Wang T. Improvement of the hepatic lipid status in intrauterine growth retarded pigs by resveratrol is related to the inhibition of mitochondrial dysfunction, oxidative stress and inflammation. Food Funct 2021;12:278-90. [PMID: 33300526 DOI: 10.1039/d0fo01459a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. [PMID: 24637477 DOI: 10.1371/journal.pone.0091987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
47 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
48 Simon TG, Roelstraete B, Hartjes K, Shah U, Khalili H, Arnell H, Ludvigsson JF. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol 2021:S0168-8278(21)01883-3. [PMID: 34224779 DOI: 10.1016/j.jhep.2021.06.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 López-Pastor AR, Infante-Menéndez J, Escribano Ó, Gómez-Hernández A. miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. Front Med (Lausanne) 2020;7:527059. [PMID: 33102495 DOI: 10.3389/fmed.2020.527059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Lu ZY, Shao Z, Li YL, Wulasihan M, Chen XH. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. World J Gastroenterol 2016; 22(13): 3663-3669 [PMID: 27053858 DOI: 10.3748/wjg.v22.i13.3663] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
51 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Reference Citation Analysis]
52 Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. PLoS One. 2019;14:e0213692. [PMID: 30870486 DOI: 10.1371/journal.pone.0213692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
53 Zhang N, Wang Y, Zhang J, Liu B, Deng X, Xin S, Xu K. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1. FASEB J 2020;34:15338-63. [PMID: 32996649 DOI: 10.1096/fj.202000836RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21(39): 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
55 Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) 2016;95:e3887. [PMID: 27281105 DOI: 10.1097/MD.0000000000003887] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 8.2] [Reference Citation Analysis]
56 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67:549-559. [PMID: 28892558 DOI: 10.1002/hep.29514] [Cited by in Crossref: 249] [Cited by in F6Publishing: 254] [Article Influence: 49.8] [Reference Citation Analysis]
58 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
59 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017;. [PMID: 28892558 DOI: 10.1002/hep.29514.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal. 2013;2013:481893. [PMID: 23576902 DOI: 10.1155/2013/481893] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
61 Zhang J, Zhang B, Cheng Y, Xu J. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine 2018;106:131-5. [DOI: 10.1016/j.cyto.2017.10.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
62 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 113] [Reference Citation Analysis]
63 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
64 Moore A, Wu L, Chuang JC, Sun X, Luo X, Gopal P, Li L, Celen C, Zimmer M, Zhu H. Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. Hepatology 2019;69:1931-45. [PMID: 30584660 DOI: 10.1002/hep.30487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
65 Weiss B, Krauthammer A, Soudack M, Lahad A, Sarouk I, Somech R, Heimer G, Ben-zeev B, Nissenkorn A. Liver Disease in Pediatric Patients With Ataxia Telangiectasia: A Novel Report. Journal of Pediatric Gastroenterology & Nutrition 2016;62:550-5. [DOI: 10.1097/mpg.0000000000001036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
66 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
67 Byrne FL, Hoehn KL. Subclassification of fatty liver by its pathogenesis: cIEFing is believing. J Pathol 2016;239:3-5. [PMID: 26880235 DOI: 10.1002/path.4702] [Reference Citation Analysis]
68 Tavakoli H, Robinson A, Liu B, Bhuket T, Younossi Z, Saab S, Ahmed A, Wong RJ. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. Dig Dis Sci. 2017;62:2174-2181. [PMID: 28474143 DOI: 10.1007/s10620-017-4595-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
69 Wang YG, Yang TL. Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. Exp Ther Med 2015;10:1777-83. [PMID: 26640549 DOI: 10.3892/etm.2015.2741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
70 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
71 Motamed N, Faraji AH, Khonsari MR, Maadi M, Tameshkel FS, Keyvani H, Ajdarkosh H, Karbalaie Niya MH, Rezaie N, Zamani F. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. Clin Nutr 2020;39:468-74. [PMID: 30922791 DOI: 10.1016/j.clnu.2019.02.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
72 Liang H, Ma LQ. Factors affecting awareness of non-alcoholic fatty liver disease among the general public and health care providers. Shijie Huaren Xiaohua Zazhi 2015; 23(33): 5303-5310 [DOI: 10.11569/wcjd.v23.i33.5303] [Reference Citation Analysis]
73 Ma X, Zhou Y, Qiao B, Jiang S, Shen Q, Han Y, Liu A, Chen X, Wei L, Zhou L, Zhao J. Androgen aggravates liver fibrosis by activation of NLRP3 inflammasome in CCl4-induced liver injury mouse model. Am J Physiol Endocrinol Metab 2020;318:E817-29. [PMID: 32182125 DOI: 10.1152/ajpendo.00427.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Zhang Y, Zhou X, Liu P, Chen X, Zhang J, Zhang H, Li S, Chen Y, Song X, Wang J, Zeng H, Zhang X, Tang C, Yu C, Li Y, Xu C. GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration. Am J Physiol Gastrointest Liver Physiol 2021;320:G531-42. [PMID: 33470903 DOI: 10.1152/ajpgi.00342.2020] [Reference Citation Analysis]
75 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
77 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab 2021. [PMID: 34622555 DOI: 10.1111/dom.14569] [Reference Citation Analysis]
78 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
79 Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-662. [PMID: 25418531 DOI: 10.1111/jdv.12847] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
80 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
81 Wang S, Zhang C, Zhang G, Yuan Z, Liu Y, Ding L, Sun X, Jia H, Xue F. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open 2016;6:e010342. [PMID: 27251683 DOI: 10.1136/bmjopen-2015-010342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
82 Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, Chan AW, Lau ESH, Ma RCW, Chan HL, Chan JC, Wong VW, Kong AP. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017;. [PMID: 28989092 DOI: 10.1016/j.jhep.2017.09.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
83 Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? European Journal of Internal Medicine 2017;46:1-5. [DOI: 10.1016/j.ejim.2017.06.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Carrascosa J, Bonanad C, Dauden E, Botella R, Olveira-martín A. Psoriasis e hígado graso no alcohólico. Actas Dermo-Sifiliográficas 2017;108:506-14. [DOI: 10.1016/j.ad.2016.12.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
85 Korkmaz H, Unler GK, Gokturk HS, Schmidt WE, Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test: . European Journal of Gastroenterology & Hepatology 2015;27:1137-43. [DOI: 10.1097/meg.0000000000000407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
86 Miller A, Jalil S, Hussan H, Kelly S, Hinton A, Hanje J, Michaels A, Conteh L, Black S, Mumtaz K. Apprising the choice of bariatric surgery in patients with compensated cirrhosis with morbid obesity: results of a national analysis. Updates Surg 2021. [PMID: 34351576 DOI: 10.1007/s13304-021-01142-z] [Reference Citation Analysis]
87 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
88 Makris KC, Andrianou XD, Charisiadis P, Burch JB, Seth RK, Ioannou A, Picolos M, Christophi CA, Chatterjee S. Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. Environment International 2016;92-93:486-93. [DOI: 10.1016/j.envint.2016.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
89 Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. [PMID: 31260793 DOI: 10.1016/j.cct.2019.06.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
90 Watanabe K, Ohta M, Takayama H, Tada K, Shitomi Y, Kawasaki T, Kawano Y, Endo Y, Iwashita Y, Inomata M. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model. OBES SURG 2018;28:1532-9. [DOI: 10.1007/s11695-017-3052-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
91 Zhang Y, Li P, Miao M, Liu Y, Pan Y, Xu L, Zhu Z, Xu C, Xu L. Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. Biomed Res Int 2018;2018:5628749. [PMID: 30112401 DOI: 10.1155/2018/5628749] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
92 Otgonsuren M, Stepanova M, Gerber L, Younossi ZM. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58:1132-1140. [PMID: 23143735 DOI: 10.1007/s10620-012-2446-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
93 Cao Y, Xu L, Chen C, Wang Y, Zhang Q, Qi R. Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. Nanomedicine 2016;12:2449-58. [PMID: 27438910 DOI: 10.1016/j.nano.2016.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol 2014; 20(39): 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 143] [Cited by in F6Publishing: 126] [Article Influence: 17.9] [Reference Citation Analysis]
95 Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784 [PMID: 28487615 DOI: 10.3748/wjg.v23.i15.2771] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
96 Guo XF, Wang C, Yang T, Li S, Li KL, Li D. Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Food Funct 2020;11:7389-99. [PMID: 32966467 DOI: 10.1039/d0fo01095b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Neves YCS, Castro-Lima VAC, Solla DJF, Ogata VSM, Pereira FL, Araujo JM, Ho YL, Chammas MC. Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. AJR Am J Roentgenol 2021;216:1392-9. [PMID: 33703928 DOI: 10.2214/AJR.20.23455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Canbay A, Sowa JP. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs 2019;79:39-44. [PMID: 30706422 DOI: 10.1007/s40265-018-1020-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
99 Kostakis ID, Sikalias N, Alexiou K, Mountzalia L, Papalois A, Karatzas T. How Much Ischemia Can the Severely Steatotic Rat Liver Tolerate? In Vivo 2018;32:1381-6. [PMID: 30348692 DOI: 10.21873/invivo.11390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Ristic-Medic D, Kovacic M, Takic M, Arsic A, Petrovic S, Paunovic M, Jovicic M, Vucic V. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.Nutrients. 2020;13:15. [PMID: 33374554 DOI: 10.3390/nu13010015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
101 Zheng Y, Zhong X, Huang Y, Zheng C. HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. Annals of Hepatology 2018;17:511-8. [DOI: 10.5604/01.3001.0011.7396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Kalidari B, Mahmoudieh M, Melali H, Nazari Moghadam M, Kolahdouzan M. Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.14088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
104 Das S, Alhasson F, Dattaroy D, Pourhoseini S, Seth RK, Nagarkatti M, Nagarkatti PS, Michelotti GA, Diehl AM, Kalyanaraman B, Chatterjee S. NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. Am J Pathol 2015;185:1944-57. [PMID: 25989356 DOI: 10.1016/j.ajpath.2015.03.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
105 Cusi K. Focus on the Type 2 Diabetes Patient with Liver Disease: Emphasis on Nonalcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 2011;17:9-13. [DOI: 10.1016/s1530-891x(20)43146-5] [Reference Citation Analysis]
106 Ponnusamy S, Tran QT, Thiyagarajan T, Miller DD, Bridges D, Narayanan R. An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. Exp Biol Med (Maywood) 2017;242:606-16. [PMID: 28092182 DOI: 10.1177/1535370216688569] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
107 Aguilar-olivos NE, Carrillo-córdova D, Oria-hernández J, Sánchez-valle V, Ponciano-rodríguez G, Ramírez-jaramillo M, Chablé-montero F, Chávez-tapia NC, Uribe M, Méndez-sánchez N. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Annals of Hepatology 2015;14:487-93. [DOI: 10.1016/s1665-2681(19)31170-6] [Cited by in Crossref: 42] [Article Influence: 6.0] [Reference Citation Analysis]
108 Abegg K, Bernasconi L, Hutter M, Whiting L, Pietra C, Giuliano C, Lutz TA, Riediger T. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease. Diabetes Obes Metab 2017;19:1740-50. [PMID: 28544245 DOI: 10.1111/dom.13020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
109 Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Res. 2017;6:1630. [PMID: 29093809 DOI: 10.12688/f1000research.12417.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
110 Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Annals of Hepatology 2012;11:172-8. [DOI: 10.1016/s1665-2681(19)31021-x] [Cited by in Crossref: 34] [Article Influence: 3.4] [Reference Citation Analysis]
111 Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(45): 6546-6551 [PMID: 23236228 DOI: 10.3748/wjg.v18.i45.6546] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 51] [Article Influence: 5.4] [Reference Citation Analysis]
112 Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, Morel-Cerda EC, Aldana-Ledesma JM, Castro-Narro GE, Cerpa-Cruz S, Tapia-Calderón DK, Mercado-Jauregui LA, Contreras-Omaña R. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. Rev Gastroenterol Mex (Engl Ed) 2019;84:472-81. [PMID: 31488310 DOI: 10.1016/j.rgmx.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
113 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
114 Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. Probiotics Antimicrob Proteins. 2017;9:123-130. [PMID: 27660157 DOI: 10.1007/s12602-016-9230-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
115 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Gallego-Durán R, Ampuero J, Funuyet J, Romero-Gómez M. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?]. Gastroenterol Hepatol. 2013;36:587-596. [PMID: 24011648 DOI: 10.1016/j.gastrohep.2013.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
117 Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. J Clin Gastroenterol 2017;51:160-6. [PMID: 27580477 DOI: 10.1097/MCG.0000000000000666] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
118 Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci 2019;16:285-91. [PMID: 30745809 DOI: 10.7150/ijms.28264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
119 Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, Hwang KB, Lee IH, Kim JI, Kong SW. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int 2015;35:2537-46. [PMID: 26148225 DOI: 10.1111/liv.12909] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
120 He DT, Chen JM, Wang B. Regulation of triglyceride metabolism by the Farnesoid X receptor. Shijie Huaren Xiaohua Zazhi 2012; 20(36): 3732-3736 [DOI: 10.11569/wcjd.v20.i36.3732] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Kaneko S. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0191026. [PMID: 29342182 DOI: 10.1371/journal.pone.0191026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
122 Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-1891. [PMID: 28774887 DOI: 10.1136/gutjnl-2017-314307] [Cited by in Crossref: 166] [Cited by in F6Publishing: 169] [Article Influence: 33.2] [Reference Citation Analysis]
123 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
124 Younossi Z, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients. Aliment Pharmacol Ther. 2015;41:209-217. [PMID: 25413020 DOI: 10.1111/apt.13027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
125 Chiyanika C, Wong VW, Wong GL, Chan HL, Hui SCN, Yeung DKW, Chu WCW. Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. Clin Transl Gastroenterol 2021;12:e00300. [PMID: 33600104 DOI: 10.14309/ctg.0000000000000300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Longo DM, Yang Y, Watkins PB, Howell BA, Siler SQ. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol 2016;5:31-9. [PMID: 26844013 DOI: 10.1002/psp4.12053] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
127 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
128 Schulz PO, Ferreira FG, Nascimento MFA, Vieira A, Ribeiro MA, David AI, Szutan LA. Association of nonalcoholic fatty liver disease and liver cancer. World J Gastroenterol 2015; 21(3): 913-918 [PMID: 25624725 DOI: 10.3748/wjg.v21.i3.913] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
129 Mori Y, Kawakami Y, Kanzaki K, Otsuki A, Kimura Y, Kanji H, Tanaka R, Tsukayama I, Hojo N, Suzuki-Yamamoto T, Kawakami T, Takahashi Y. Arachidonate 12S-lipoxygenase of platelet-type in hepatic stellate cells of methionine and choline-deficient diet-fed mice. J Biochem. 2020;168:455-463. [PMID: 32492133 DOI: 10.1093/jb/mvaa062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
131 Hsu JH, Chien IC, Lin CH. Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study. Gen Hosp Psychiatry 2016;42:54-9. [PMID: 27638973 DOI: 10.1016/j.genhosppsych.2016.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
132 Mądry E, Malesza IJ, Subramaniapillai M, Czochralska-Duszyńska A, Walkowiak M, Miśkiewicz-Chotnicka A, Walkowiak J, Lisowska A. Body Fat Changes and Liver Safety in Obese and Overweight Women Supplemented with Conjugated Linoleic Acid: A 12-Week Randomised, Double-Blind, Placebo-Controlled Trial. Nutrients 2020;12:E1811. [PMID: 32560516 DOI: 10.3390/nu12061811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Yarrington CD, Cantonwine DE, Seely EW, Mcelrath TF, Zera CA. The association of early unexplained elevated alanine aminotransferase with large-for-gestational-age birthweight. American Journal of Obstetrics and Gynecology 2016;215:474.e1-5. [DOI: 10.1016/j.ajog.2016.04.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
134 Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology 2016;14:5-12. [DOI: 10.1016/j.cgh.2015.05.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
135 Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012;59:442-9. [DOI: 10.1016/j.cyto.2012.05.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
136 Amin RF, El Bendary AS, Ezzat SE, Mohamed WS. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients. Diabetes Metab Syndr 2019;13:2226-9. [PMID: 31235161 DOI: 10.1016/j.dsx.2019.05.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
137 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Sharma A, Anand SK, Singh N, Dwivedi UN, Kakkar P. Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells. Eur J Pharmacol 2020;882:173244. [PMID: 32526241 DOI: 10.1016/j.ejphar.2020.173244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
139 Lee YS, Kim SY, Ko E, Lee JH, Yi HS, Yoo YJ, Je J, Suh SJ, Jung YK, Kim JH, Seo YS, Yim HJ, Jeong WI, Yeon JE, Um SH, Byun KS. Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. Sci Rep. 2017;7:3710. [PMID: 28623272 DOI: 10.1038/s41598-017-03389-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 15.6] [Reference Citation Analysis]
140 Kappus M, Abdelmalek M. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017;21:321-35. [DOI: 10.1016/j.cld.2016.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
141 Lee JH, Lee HS, Lee BK, Kwon YJ, Lee JW. Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. Biology (Basel) 2021;10:122. [PMID: 33562473 DOI: 10.3390/biology10020122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Kadowaki T, Haneda M, Ito H, Sasaki K, Hiraide S, Matsukawa M, Ueno M. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. Adv Ther. 2018;35:817-831. [PMID: 29777520 DOI: 10.1007/s12325-018-0704-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
143 Wáng YXJ. Gender-specific liver aging and magnetic resonance imaging. Quant Imaging Med Surg 2021;11:2893-904. [PMID: 34249621 DOI: 10.21037/qims-21-227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Polyzos SA, Kountouras J, Tsatsoulis A, Zafeiriadou E, Katsiki E, Patsiaoura K, Zavos C, Anastasiadou VV, Slavakis A. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones (Athens) 2013;12:405-16. [PMID: 24121382 DOI: 10.1007/BF03401306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
145 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725.e6. [PMID: 22326434 DOI: 10.1053/j.gastro.2012.02.003] [Cited by in Crossref: 482] [Cited by in F6Publishing: 450] [Article Influence: 48.2] [Reference Citation Analysis]
146 Kahraman A, Sowa JP, Schlattjan M, Sydor S, Pronadl M, Wree A, Beilfuss A, Kilicarslan A, Altinbaş A, Bechmann LP, Syn WK, Gerken G, Canbay A. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond) 2013;125:391-400. [PMID: 23627434 DOI: 10.1042/CS20120542] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
147 Lewis PL, Shah RN. 3D Printing for Liver Tissue Engineering: Current Approaches and Future Challenges. Curr Transpl Rep 2016;3:100-8. [DOI: 10.1007/s40472-016-0084-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
148 Sodhi K, Puri N, Favero G, Stevens S, Meadows C, Abraham NG, Rezzani R, Ansinelli H, Lebovics E, Shapiro JI. Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet. PLoS One 2015;10:e0128648. [PMID: 26098879 DOI: 10.1371/journal.pone.0128648] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
149 Mohanty A, Fortune BE. Why Pursue a Fourth Year in Advanced/Transplant Hepatology? Dig Dis Sci 2016;61:1817-8. [PMID: 26971091 DOI: 10.1007/s10620-016-4108-3] [Reference Citation Analysis]
150 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. BMJ Open 2019;9:e031420. [PMID: 31492793 DOI: 10.1136/bmjopen-2019-031420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
152 van Tienhoven-Wind LJ, Dullaart RP. Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients 2015;7:1352-77. [PMID: 25690422 DOI: 10.3390/nu7021352] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
153 Wang B, Qu Y, Wang Y, Ma Y, Xu C, Li F, Liu C, Lu X, Wang B, Xiu P, Gao Y, Diao Z, Li Y, Luo H. Triplet Male Lambs Are More Susceptible than Twins to Dietary Soybean Oil-Induced Fatty Liver. J Nutr 2019;149:989-95. [PMID: 31070764 DOI: 10.1093/jn/nxz039] [Reference Citation Analysis]
154 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
155 Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ 2014;349:g4596. [PMID: 25239614 DOI: 10.1136/bmj.g4596] [Cited by in Crossref: 157] [Cited by in F6Publishing: 148] [Article Influence: 19.6] [Reference Citation Analysis]
156 Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Carnevale R, Loffredo L, Pignatelli P, Violi F, Angelico F. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. Int J Hepatol 2014;2014:784985. [PMID: 24678423 DOI: 10.1155/2014/784985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
157 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
158 Auguet T, Berlanga A, Guiu-Jurado E, Terra X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernández M, Del Castillo D, Richart C. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed Res Int 2014;2014:502542. [PMID: 24864249 DOI: 10.1155/2014/502542] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
159 Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, Stravitz RT, Puri P, Matherly S, Sterling RK. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000-1008.e3. [PMID: 25311381 DOI: 10.1016/j.cgh.2014.10.008] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
160 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
161 Pietzner M, Budde K, Homuth G, Kastenmüller G, Henning AK, Artati A, Krumsiek J, Völzke H, Adamski J, Lerch MM, Kühn JP, Nauck M, Friedrich N. Hepatic Steatosis Is Associated With Adverse Molecular Signatures in Subjects Without Diabetes. J Clin Endocrinol Metab 2018;103:3856-68. [PMID: 30060179 DOI: 10.1210/jc.2018-00999] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
162 Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210. [PMID: 25884354 DOI: 10.1186/s12885-015-1197-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
163 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-133. [PMID: 28802062 DOI: 10.1002/hep.29466] [Cited by in Crossref: 594] [Cited by in F6Publishing: 568] [Article Influence: 118.8] [Reference Citation Analysis]
164 Del Ben M, Overi D, Polimeni L, Carpino G, Labbadia G, Baratta F, Pastori D, Noce V, Gaudio E, Angelico F, Mancone C. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. Int J Mol Sci 2018;19:E603. [PMID: 29463024 DOI: 10.3390/ijms19020603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
165 Wu Q, Liu J, Liu L, Chen Y, Wang J, Leng L, Yu Q, Duan Z, Wang Y. Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. ACS Biomater Sci Eng 2018;4:3016-26. [DOI: 10.1021/acsbiomaterials.8b00652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
166 Lopez-Delgado JC, Esteve F, Javierre C, Ventura JL, Mañez R, Farrero E, Torrado H, Rodríguez-Castro D, Carrio ML. Influence of cirrhosis in cardiac surgery outcomes. World J Hepatol 2015; 7(5): 753-760 [PMID: 25914775 DOI: 10.4254/wjh.v7.i5.753] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
167 Yu AH, Duan-Mu YY, Zhang Y, Wang L, Guo Z, Yu YQ, Wang YS, Cheng XG. Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. Korean J Radiol. 2018;19:923-929. [PMID: 30174482 DOI: 10.3348/kjr.2018.19.5.923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
168 Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, Ikhwan MA, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R; Familial NAFLD Cirrhosis Research Consortium. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127:2697-704. [PMID: 28628033 DOI: 10.1172/JCI93465] [Cited by in Crossref: 72] [Cited by in F6Publishing: 36] [Article Influence: 14.4] [Reference Citation Analysis]
169 Mullin GE. Vitamin E for Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2011;26:636-7. [DOI: 10.1177/0884533611418343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
170 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
171 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
172 Hugenholtz GC, Northup PG, Porte RJ, Lisman T. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy? Blood Rev. 2015;29:127-136. [PMID: 25468718 DOI: 10.1016/j.blre.2014.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
173 Ministrini S, Calzini L, Nulli Migliola E, Ricci MA, Roscini AR, Siepi D, Tozzi G, Daviddi G, Martorelli EE, Paganelli MT, Lupattelli G. Lysosomal Acid Lipase as a Molecular Target of the Very Low Carbohydrate Ketogenic Diet in Morbidly Obese Patients: The Potential Effects on Liver Steatosis and Cardiovascular Risk Factors. J Clin Med 2019;8:E621. [PMID: 31067824 DOI: 10.3390/jcm8050621] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
174 Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World J Gastroenterol 2021; 27(6): 523-533 [PMID: 33642826 DOI: 10.3748/wjg.v27.i6.523] [Reference Citation Analysis]
175 Zelber-sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, Santo E, Oren R, Shibolet O. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014;34:e128-35. [DOI: 10.1111/liv.12318] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
176 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
177 Mansour-ghanaei F, Joukar F, Mobaraki SN, Mavaddati S, Hassanipour S, Sepehrimanesh M. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:1591-6. [DOI: 10.1016/j.dsx.2019.03.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
178 Mazzone L, Postorino V, De Peppo L, Della Corte C, Lofino G, Vassena L, Fatta L, Armando M, Bedogni G, Vicari S, Nobili V. Paediatric non-alcoholic Fatty liver disease: impact on patients and mothers' quality of life. Hepat Mon 2013;13:e7871. [PMID: 23745129 DOI: 10.5812/hepatmon.7871] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
179 Lee JH, Lee HS, Ahn SB, Kwon YJ. Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. Clin Nutr 2021;40:5252-60. [PMID: 34534894 DOI: 10.1016/j.clnu.2021.08.012] [Reference Citation Analysis]
180 Semrau JD, Dispirito AA. Methanobactin: A Novel Copper-Binding Compound Produced by Methanotrophs. In: Lee EY, editor. Methanotrophs. Cham: Springer International Publishing; 2019. pp. 205-29. [DOI: 10.1007/978-3-030-23261-0_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, Selvaraj V. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep 2017;7:6120. [PMID: 28733574 DOI: 10.1038/s41598-017-05040-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
182 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 21.5] [Reference Citation Analysis]
183 Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352-60. [DOI: 10.1016/j.metabol.2012.08.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 10.0] [Reference Citation Analysis]
184 Zsóri G, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord 2019;17:289-95. [PMID: 31013454 DOI: 10.1089/met.2018.0086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
185 Houghton-Rahrig LD, Schutte DL, von Eye A, Fenton JI, Given BA, Hord NG. Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease. Nurs Outlook 2013;61:242-251.e2. [PMID: 23849554 DOI: 10.1016/j.outlook.2013.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
186 Yi HW, Zhu XX, Huang XL, Lai YZ, Tang Y. Selenium-enriched Bifidobacterium longum protected alcohol and high fat diet induced hepatic injury in mice. Chin J Nat Med 2020;18:169-77. [PMID: 32245586 DOI: 10.1016/S1875-5364(20)30018-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
187 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
188 Vos MB. Is it time to advance pediatric NAFLD diagnosis to the magnetic resonance imaging era? Hepatology 2015;61:1779-80. [PMID: 25809113 DOI: 10.1002/hep.27808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
189 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
190 Wakiya T, Ishido K, Kudo D, Kimura N, Sato K, Mitsuhashi Y, Kagiya T, Uchida C, Umetsu S, Yoshida T, Wakasa Y, Toyoki Y, Hakamada K. Impact of Smoking Cessation in Donor Candidates for Living Donor Liver Transplantation. Transplant Proc 2018;50:2593-6. [PMID: 30401357 DOI: 10.1016/j.transproceed.2018.02.201] [Reference Citation Analysis]
191 Lee JH, Lee HS, Cho AR, Lee YJ, Kwon YJ. Non-Alcoholic Fatty Liver Disease Is an Independent Risk Factor for LDL Cholesterol Target Level. Int J Environ Res Public Health 2021;18:3442. [PMID: 33810315 DOI: 10.3390/ijerph18073442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 López-Reyes A, Clavijo-Cornejo D, Fernández-Torres J, Medina-Luna D, Estrada-Villaseñor EG, Gómez-Quiroz LE, Gutiérrez M, Granados J, Vargas-Alarcón G, Pineda C, García H, Morales-Garza LA, Gutiérrez-Ruiz MC, Martínez-Flores K. Fast Morphological Gallbladder Changes Triggered by a Hypercholesterolemic Diet. Ann Hepatol 2018;17:857-63. [PMID: 30145572 DOI: 10.5604/01.3001.0012.3160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, Kis O, Fliss-Isakov N, Izkhakov E, Halpern Z, Santo E, Oren R, Shibolet O. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014; 20(15): 4382-4392 [PMID: 24764677 DOI: 10.3748/wjg.v20.i15.4382] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 58] [Article Influence: 8.5] [Reference Citation Analysis]
194 Siddiqui MS, Cheang KL, Luketic VA, Boyett S, Idowu MO, Patidar K, Puri P, Matherly S, Stravitz RT, Sterling RK, Sanyal AJ. Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function. Dig Dis Sci 2015;60:2529-37. [PMID: 25784075 DOI: 10.1007/s10620-015-3627-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
195 Khurana S, Butt W, Khara HS, Johal AS, West SF, Chen ZE, Berger AL, Diehl DL. Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. Hepatol Int 2019;13:323-9. [DOI: 10.1007/s12072-019-09945-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
196 Enos RT, Velázquez KT, McClellan JL, Cranford TL, Walla MD, Murphy EA. Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model. Nutr Res 2015;35:449-59. [PMID: 25934114 DOI: 10.1016/j.nutres.2015.04.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
197 Polyzos SA, Kountouras J, Slavakis A, Zafeiriadou E, Patsiaoura K, Katsiki E, Zavos C, Papatheodorou A, Terpos E. A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers 2013;18:607-13. [DOI: 10.3109/1354750x.2013.838305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
198 Huang HC, Tsai MH, Lee FY, Lin TY, Chang CC, Chuang CL, Hsu SJ, Hou MC, Huang YH. NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11β-HSDs Dysregulation in Rats. Pharmaceutics 2020;12:E403. [PMID: 32354071 DOI: 10.3390/pharmaceutics12050403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Han EN, Cheong ES, Lee JI, Kim MC, Byrne CD, Sung KC. Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. Clin Hypertens 2015;21:22. [PMID: 26893932 DOI: 10.1186/s40885-015-0032-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
200 Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, Mathurin P, Gournay J, Nguyen-khac E, De Ledinghen V, Larrey D, Tran A, Bourliere M, Maynard-muet M, Asselah T, Henrion J, Nevens F, Cassiman D, Geerts A, Moreno C, Beuers U, Galle P, Spengler U, Bugianesi E, Craxi A, Angelico M, Fargion S, Voiculescu M, Gheorghe L, Preotescu L, Caballeria J, Andrade R, Crespo J, Callera J, Ala A, Aithal G, Abouda G, Luketic V, Huang M, Gordon S, Pockros P, Poordad F, Shores N, Moehlen M, Bambha K, Clark V, Satapathy S, Parekh S, Reddy R, Sheikh M, Szabo G, Vierling J, Foster T, Umpierrez G, Chang C, Box T, Gallegos-orozco J. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:1147-1159.e5. [DOI: 10.1053/j.gastro.2016.01.038] [Cited by in Crossref: 533] [Cited by in F6Publishing: 499] [Article Influence: 88.8] [Reference Citation Analysis]
201 Nobili V, Bedogni G, Berni Canani R, Brambilla P, Cianfarani S, Pietrobelli A, Agostoni C. The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk? Pediatr Obes 2012;7:e75-80. [PMID: 23001964 DOI: 10.1111/j.2047-6310.2012.00089.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
202 Cheng Y, Hou T, Ping J, Chen G, Chen J. Quantitative succinylome analysis in the liver of non-alcoholic fatty liver disease rat model. Proteome Sci 2016;14:3. [PMID: 26843850 DOI: 10.1186/s12953-016-0092-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
203 Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, Liss KH, Klein S, Feldstein AE, Finck BN, Artyomov MN, Schilling JD. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep 2021;34:108626. [PMID: 33440159 DOI: 10.1016/j.celrep.2020.108626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
204 Sheikh MY, Raoufi R, Atla PR, Riaz M, Oberer C, Moffett MJ. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. Saudi J Gastroenterol 2012;18:257-62. [PMID: 22824769 DOI: 10.4103/1319-3767.98431] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
205 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
206 Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8263-8276 [PMID: 29307986 DOI: 10.3748/wjg.v23.i47.8263] [Cited by in CrossRef: 252] [Cited by in F6Publishing: 225] [Article Influence: 50.4] [Reference Citation Analysis]
207 Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 2018;67:2001-12. [PMID: 29059456 DOI: 10.1002/hep.29607] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 15.8] [Reference Citation Analysis]
208 Basu PP, Aloysius MM, Shah NJ, Brown RS. Review article: the endocannabinoid system in liver disease, a potential therapeutic target. Aliment Pharmacol Ther. 2014;39:790-801. [PMID: 24612021 DOI: 10.1111/apt.12673] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
209 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
210 Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol 2017; 9(10): 503-509 [PMID: 28443155 DOI: 10.4254/wjh.v9.i10.503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
211 Wang T, Pan W, Hu J, Zhang Z, Li G, Liang Y. Circular RNAs in Metabolic Diseases. Adv Exp Med Biol 2018;1087:275-85. [PMID: 30259374 DOI: 10.1007/978-981-13-1426-1_22] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
212 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
213 Keramida G, Gregg S, Peters AM. Intrahepatic fluorine-18-fluorodeoxyglucose kinetics measured by least squares nonlinear computer modelling and Gjedde–Patlak–Rutland graphical analysis. Nuclear Medicine Communications 2019;40:675-83. [DOI: 10.1097/mnm.0000000000001023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
214 Zatu MC, van Rooyen JM, Loots du T, Greeff M, Schutte AE. A comparison of the cardiometabolic profile of black South Africans with suspected non-alcoholic fatty liver disease (NAFLD) and excessive alcohol use. Alcohol 2015;49:165-72. [PMID: 25543202 DOI: 10.1016/j.alcohol.2014.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
215 Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
216 Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:144. [PMID: 33794784 DOI: 10.1186/s12876-021-01660-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Cobbold JFL, Patel D, Taylor-robinson SD. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques: Imaging in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2012;27:1281-92. [DOI: 10.1111/j.1440-1746.2012.07127.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
218 Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M, Mochizuki H. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013;84:62-70. [PMID: 23592516 DOI: 10.1124/mol.112.084269] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
219 Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. Am J Gastroenterol 2021;116:116-24. [PMID: 33027082 DOI: 10.14309/ajg.0000000000000845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
220 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
221 Yao J, Zhao Y, Zhang J, Hong Y, Lu H, Wu J. Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients. Lipids Health Dis 2014;13:185. [PMID: 25481429 DOI: 10.1186/1476-511X-13-185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
222 Moore MP, Cunningham RP, Kelty TJ, Boccardi LR, Nguyen NY, Booth FW, Rector RS. Ketogenic diet in combination with voluntary exercise impacts markers of hepatic metabolism and oxidative stress in male and female Wistar rats. Appl Physiol Nutr Metab 2020;45:35-44. [PMID: 31116955 DOI: 10.1139/apnm-2019-0042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
223 Gao Y, Lu J, Liu X, Liu J, Ma Q, Shi Y, Su H. Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. Front Physiol 2021;12:748517. [PMID: 34880774 DOI: 10.3389/fphys.2021.748517] [Reference Citation Analysis]
224 Elzouki AN. Probiotics and Liver Disease: Where Are We Now and Where Are We Going? J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & amp; New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S188-S190. [PMID: 27741172 DOI: 10.1097/mcg.0000000000000712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
225 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
226 Brunner KT, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Increasing liver fat is associated with progression of cardiovascular risk factors. Liver Int 2020;40:1339-43. [PMID: 32301571 DOI: 10.1111/liv.14472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
227 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol. 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Ehsani MJ, Mahdavi Jafari J, Aliasl J, Kamalinejad M, Gachkar L, Choopani R. Effect of diet based on the principles of Iranian traditional medicine on cirrhosis (a clinical trial). Complement Ther Med 2016;29:35-41. [PMID: 27912954 DOI: 10.1016/j.ctim.2016.09.006] [Reference Citation Analysis]
229 de la Monte SM. Relationships between diabetes and cognitive impairment. Endocrinol Metab Clin North Am. 2014;43:245-267. [PMID: 24582101 DOI: 10.1016/j.ecl.2013.09.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
230 Yue W, Sun X, Du T. Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. BMC Endocr Disord 2019;19:95. [PMID: 31477078 DOI: 10.1186/s12902-019-0423-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
231 Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol 2013; 5(5): 281-287 [PMID: 23717739 DOI: 10.4254/wjh.v5.i5.281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
232 Ergelen R, Akyuz U, Aydin Y, Eren F, Yilmaz Y. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015;27:667-71. [DOI: 10.1097/meg.0000000000000342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
233 Henry ZH, Argo CK. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 2020;49:45-62. [DOI: 10.1016/j.gtc.2019.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Goyale A, Jain A, Smith C, Papatheodoridi M, Misas MG, Roccarina D, Prat LI, Mikhailidis DP, Nair D, Tsochatzis E. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One 2021;16:e0260313. [PMID: 34813621 DOI: 10.1371/journal.pone.0260313] [Reference Citation Analysis]
235 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 919] [Article Influence: 144.3] [Reference Citation Analysis]
236 Xu M, Zheng XM, Jiang F, Qiu WQ. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem 2018;119:5864-74. [PMID: 29575055 DOI: 10.1002/jcb.26776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
237 Chung GE, Kim D. Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. Clin Mol Hepatol 2013;19:116-9. [PMID: 23837135 DOI: 10.3350/cmh.2013.19.2.116] [Reference Citation Analysis]
238 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Sekkarie A, Welsh JA, Northstone K, Stein AD, Ramakrishnan U, Vos MB. Associations between Free Sugar and Sugary Beverage Intake in Early Childhood and Adult NAFLD in a Population-Based UK Cohort. Children (Basel) 2021;8:290. [PMID: 33917875 DOI: 10.3390/children8040290] [Reference Citation Analysis]
240 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
241 Cunningham RP, Sheldon RD, Rector RS. The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development. Front Physiol 2020;11:767. [PMID: 32719616 DOI: 10.3389/fphys.2020.00767] [Reference Citation Analysis]
242 Harada N, Hanaoka R, Hanada K, Izawa T, Inui H, Yamaji R. Hypogonadism alters cecal and fecal microbiota in male mice. Gut Microbes. 2016;7:533-539. [PMID: 27656762 DOI: 10.1080/19490976.2016.1239680] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
243 Fu S, Yu M, Tan Y, Liu D. Role of histone deacetylase on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:353-61. [PMID: 33213187 DOI: 10.1080/17474124.2021.1854089] [Reference Citation Analysis]
244 Chen K, Chen X, Xue H, Zhang P, Fang W, Chen X, Ling W. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. Food Funct 2019;10:814-23. [DOI: 10.1039/c8fo01236a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 8.3] [Reference Citation Analysis]
245 Kwon EY, Lee J, Kim YJ, Do A, Choi JY, Cho SJ, Jung UJ, Lee MK, Park YB, Choi MS. Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity. Nutrients 2017;9:E569. [PMID: 28574484 DOI: 10.3390/nu9060569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
246 Kim HM, Lee YH. The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008-2011). Endocrinol Metab (Seoul) 2021. [PMID: 34809412 DOI: 10.3803/EnM.2021.1087] [Reference Citation Analysis]
247 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
248 Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30-43. [PMID: 26407715 DOI: 10.1007/s00125-015-3769-3] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 15.7] [Reference Citation Analysis]
249 Kozlitina J. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020;49:25-44. [PMID: 32033763 DOI: 10.1016/j.gtc.2019.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
250 Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092-2103.e1-6. [PMID: 24582567 DOI: 10.1016/j.cgh.2014.02.024] [Cited by in Crossref: 172] [Cited by in F6Publishing: 163] [Article Influence: 21.5] [Reference Citation Analysis]
251 Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 2016; 22(48): 10512-10522 [PMID: 28082803 DOI: 10.3748/wjg.v22.i48.10512] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 182] [Article Influence: 33.0] [Reference Citation Analysis]
252 Sato T, Tsuchiya A, Owaki T, Kumagai M, Motegi S, Iwasawa T, Nojiri S, Ogawa M, Takeuchi S, Watanabe Y, Kawata Y, Kamimura H, Terai S. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;566:36-44. [PMID: 34116355 DOI: 10.1016/j.bbrc.2021.05.097] [Reference Citation Analysis]
253 Su Y, Liu Z, Yang L, Li Y, Jiang S, Yao H, Du G. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. Clin Res Hepatol Gastroenterol 2020;44:894-904. [PMID: 32505733 DOI: 10.1016/j.clinre.2020.02.005] [Reference Citation Analysis]
254 Safarian M, Mohammadpour S, Shafiee M, Ganji A, Soleimani A, Nematy M, Bahari A. Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. Diabetes Metab Syndr 2019;13:989-94. [PMID: 31336557 DOI: 10.1016/j.dsx.2019.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
255 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
256 Georgoulis M, Fragopoulou E, Kontogianni MD, Margariti A, Boulamatsi O, Detopoulou P, Tiniakos D, Zafiropoulou R, Papatheodoridis G. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. Nutr Res 2015;35:41-8. [PMID: 25530013 DOI: 10.1016/j.nutres.2014.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
257 Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, Benjamin EJ, Levy D, Fox CS, Long MT. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66:390-397. [PMID: 27729222 DOI: 10.1016/j.jhep.2016.09.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
258 Macías J, Real LM, Rivero-Juárez A, Merchante N, Camacho A, Neukam K, Rivero A, Mancebo M, Pineda JA. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med 2016;17:766-73. [PMID: 27028546 DOI: 10.1111/hiv.12384] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
259 Kim HJ, Lim CW, Lee JH, Park HB, Suh Y, Cho YH, Choi TY, Hwang ES, Cho DK. Gender-based differences in the relationship between fatty liver disease and atherosclerosis. Cardiovasc J Afr 2016;27:281-6. [PMID: 26972662 DOI: 10.5830/CVJA-2016-014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
260 Dullaart RP, van den Berg EH, van der Klauw MM, Blokzijl H. Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people. Clinical Biochemistry 2014;47:1028-32. [DOI: 10.1016/j.clinbiochem.2014.04.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
261 Nyberg LM, Cheetham TC, Patton HM, Yang SJ, Chiang KM, Caparosa SL, Stern JA, Nyberg AH. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. Hepatol Commun 2021;5:83-96. [PMID: 33437903 DOI: 10.1002/hep4.1625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
262 Bica C, Sandu C, Suceveanu AI, Sarbu E, Stoica RA, Gherghiceanu F, Bohiltea RE, Stefan SD, Stoian AP. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Exp Ther Med 2020;20:2387-91. [PMID: 32765720 DOI: 10.3892/etm.2020.8882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
263 Li Y, Cao C, Zhou Y, Nie Y, Cao J, Zhou Y. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. Arab Journal of Gastroenterology 2020;21:162-8. [DOI: 10.1016/j.ajg.2020.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
264 Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol. 2013;108:1299-1304. [PMID: 23567356 DOI: 10.1038/ajg.2013.104] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 10.8] [Reference Citation Analysis]
265 Xiong J, Wang J, Huang J, Sun W, Wang J, Chen D. Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: a ten-year retrospective study. Clinics (Sao Paulo) 2015;70:563-8. [PMID: 26247669 DOI: 10.6061/clinics/2015(08)06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
266 Gawrieh S, Chalasani N. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:189-99. [PMID: 29128056 DOI: 10.1016/j.cld.2017.08.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
267 Zhu R, Baker SS, Moylan CA, Abdelmalek MF, Guy CD, Zamboni F, Wu D, Lin W, Liu W, Baker RD, Govindarajan S, Cao Z, Farci P, Diehl AM, Zhu L. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers: Elevated alcohol-metabolizing genes in NAFLD. J Pathol 2016;238:531-42. [DOI: 10.1002/path.4650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
268 Siersbæk M, Varticovski L, Yang S, Baek S, Nielsen R, Mandrup S, Hager GL, Chung JH, Grøntved L. High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss. Sci Rep 2017;7:40220. [PMID: 28071704 DOI: 10.1038/srep40220] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
269 Jump DB, Lytle KA, Depner CM, Tripathy S. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. Pharmacol Ther 2018;181:108-25. [PMID: 28723414 DOI: 10.1016/j.pharmthera.2017.07.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
270 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol 2018; 10(1): 142-154 [PMID: 29399288 DOI: 10.4254/wjh.v10.i1.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
272 Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953-966. [PMID: 24750664 DOI: 10.1111/liv.12570] [Cited by in Crossref: 164] [Cited by in F6Publishing: 153] [Article Influence: 20.5] [Reference Citation Analysis]
273 Cao X, Gu Y, Bian S, Zhang Q, Meng G, Liu L, Wu H, Zhang S, Wang Y, Zhang T, Wang X, Sun S, Wang X, Jia Q, Song K, Niu K. Association between eating speed and newly diagnosed nonalcoholic fatty liver disease among the general population. Nutr Res 2020;80:78-88. [PMID: 32736293 DOI: 10.1016/j.nutres.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
274 Pfirrmann D, Haller N, Huber Y, Jung P, Lieb K, Gockel I, Poplawska K, Schattenberg JM, Simon P. Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. JMIR Res Protoc 2018;7:e106. [PMID: 29789277 DOI: 10.2196/resprot.8607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
275 Olafsson S, Rögnvaldsson S, Bergmann OM, Jonasson JG, Benitez Hernandez U, Björnsson ES. A nationwide population-based prospective study of cirrhosis in Iceland. JHEP Rep 2021;3:100282. [PMID: 34041467 DOI: 10.1016/j.jhepr.2021.100282] [Reference Citation Analysis]
276 Hahn L, Reeder SB, Muñoz del Rio A, Pickhardt PJ. Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. AJR Am J Roentgenol 2015;205:1167-72. [PMID: 26587921 DOI: 10.2214/AJR.15.14724] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
277 Pang Q, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, Liu C. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol 2015; 21(5): 1650-1662 [PMID: 25663786 DOI: 10.3748/wjg.v21.i5.1650] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
278 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
279 Yan Z, Chen FQ. Effect of chronic hepatitis B on liver function, serum lipids, blood glucose and insulin in patients with NAFLD. Shijie Huaren Xiaohua Zazhi 2016; 24(23): 3523-3528 [DOI: 10.11569/wcjd.v24.i23.3523] [Reference Citation Analysis]
280 Kwon HM, Hwang GS. Cardiovascular dysfunction and liver transplantation. Korean J Anesthesiol 2018;71:85-91. [PMID: 29619780 DOI: 10.4097/kjae.2018.71.2.85] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
281 de Gracia Hahn D, Duret A, Mann JP. An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. Am J Gastroenterol 2019;114:556-9. [PMID: 30951517 DOI: 10.14309/ajg.0000000000000193] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 22.0] [Reference Citation Analysis]
283 Espe M, Vikeså V, Helgøy Thomsen T, Adam A, Saito T, Skjærven KH. Atlantic salmon fed a nutrient package of surplus methionine, vitamin B12, folic acid and vitamin B6 improved growth and reduced the relative liver size, but when in excess growth reduced. Aquacult Nutr 2019;26:477-89. [DOI: 10.1111/anu.13010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
284 Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int 2016;36:1688-95. [PMID: 27064133 DOI: 10.1111/liv.13144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
285 Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Res A Clin Mol Teratol 2015;103:787-93. [PMID: 26033770 DOI: 10.1002/bdra.23363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
286 Swain M, Nath P, Parida PK, Narayan J, Padhi PK, Pati GK, Singh A, Misra B, Misra D, Kar SK, Panigrahi MK, Meher C, Agrawal O, Rout N, Pattnaik K, Bhuyan P, Mishra PK, Singh SP. Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian J Clin Biochem 2017;32:306-14. [PMID: 28811690 DOI: 10.1007/s12291-016-0612-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
287 Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 2015; 7(28): 2811-2818 [PMID: 26668692 DOI: 10.4254/wjh.v7.i28.2811] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
288 Wang JW, Wan XY, Zhu HT, Lu C, Yu WL, Yu CH, Shen Z, Li YM. Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells. PLoS One 2014;9:e96124. [PMID: 24788149 DOI: 10.1371/journal.pone.0096124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
289 Ham JR, Lee H, Choi R, Sim M, Choi M, Kwon E, Yun KW, Kim M, Lee M. Anti-obesity and anti-hepatosteatosis effects of dietary scopoletin in high-fat diet fed mice. Journal of Functional Foods 2016;25:433-46. [DOI: 10.1016/j.jff.2016.06.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
290 Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. [PMID: 33037056 DOI: 10.1136/gutjnl-2020-322786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
291 Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011;22:479-88. [PMID: 22002020 DOI: 10.1097/MOL.0b013e32834c7cfc] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
292 Herath HMM, Kodikara I, Weerarathna TP, Liyanage G. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:246-50. [DOI: 10.1016/j.dsx.2018.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
293 Poekes L, Gillard J, Farrell GC, Horsmans Y, Leclercq IA. Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. Lab Invest 2019;99:4-16. [PMID: 30258096 DOI: 10.1038/s41374-018-0120-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
294 Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Wróblewski T, Remiszewski P, Grodzicki M, Krawczyk M. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial. Ann Surg 2017;266:738-45. [PMID: 28767558 DOI: 10.1097/SLA.0000000000002397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 8.6] [Reference Citation Analysis]
295 Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47:4-11. [PMID: 25224698 DOI: 10.1016/j.dld.2014.07.170] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 11.1] [Reference Citation Analysis]
296 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
297 Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Res 2018;3:166. [PMID: 30687796 DOI: 10.12688/wellcomeopenres.14974.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
298 Jiang ZG, Tsugawa Y, Tapper EB, Lai M, Afdhal N, Robson SC, Mukamal KJ. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2015;42:106-16. [DOI: 10.1111/apt.13216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
299 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
300 Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl) 2018;8:21-9. [PMID: 29785393 DOI: 10.2147/PTT.S141629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
301 Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep 2021;3:100293. [PMID: 34179738 DOI: 10.1016/j.jhepr.2021.100293] [Reference Citation Analysis]
302 Vrtílek M, Žák J, Blažek R, Polačik M, Cellerino A, Reichard M. Limited scope for reproductive senescence in wild populations of a short-lived fish. Sci Nat 2018;105. [DOI: 10.1007/s00114-018-1594-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
303 Lankarani KB, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Ghaffarpasand F, Fallahzadeh MK, Babaeinejad M, Maharlouei N, Mirzaee O, Geramizadeh B, Peymani P. Common Carotid Intima-media Thickness in Patients with Non-alcoholic Fatty Liver Disease: A Population-based Case-control Study. Korean J Gastroenterol 2013;62:344. [DOI: 10.4166/kjg.2013.62.6.344] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
304 Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, Bettencourt R, Collier S, Hooker J, Sy E, Rizo E, Richards L, Sirlin CB, Loomba R. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348-1359. [PMID: 29108123 DOI: 10.1002/hep.29639] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 27.0] [Reference Citation Analysis]
305 Dioguardi Burgio M, Ronot M, Reizine E, Rautou P, Castera L, Paradis V, Garteiser P, Van Beers B, Vilgrain V. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol 2020;30:2293-301. [DOI: 10.1007/s00330-019-06480-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
306 Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertility and Sterility 2018;110:794-809. [DOI: 10.1016/j.fertnstert.2018.08.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
307 Singal AK, Arsalan A, Dunn W, Arab JP, Wong RJ, Kuo YF, Kamath PS, Shah VH. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther 2021;54:451-61. [PMID: 34247424 DOI: 10.1111/apt.16461] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
308 Kozłowska-Petriczko K, Wunsch E, Petriczko J, Syn WK, Milkiewicz P. Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. J Clin Med 2021;10:1507. [PMID: 33916626 DOI: 10.3390/jcm10071507] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
309 Stefano JT, Pereira IV, Torres MM, Bida PM, Coelho AM, Xerfan MP, Cogliati B, Barbeiro DF, Mazo DF, Kubrusly MS, D'Albuquerque LA, Souza HP, Carrilho FJ, Oliveira CP. Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. Braz J Med Biol Res 2015;48:408-14. [PMID: 25714891 DOI: 10.1590/1414-431X20143962] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
310 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
311 Liu MX, Gao M, Li CZ, Yu CZ, Yan H, Peng C, Li Y, Li CG, Ma ZL, Zhao Y. Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis. Acta Pharmacol Sin. 2017;38:660-671. [PMID: 28112179 DOI: 10.1038/aps.2016.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
312 Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, Diehl AM, Moylan CA. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:608-17. [PMID: 33860119 DOI: 10.1002/hep4.1665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
314 Coulon S, Legry V, Heindryckx F, Van Steenkiste C, Casteleyn C, Olievier K, Libbrecht L, Carmeliet P, Jonckx B, Stassen JM. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology. 2013;57:1793-1805. [PMID: 23299577 DOI: 10.1002/hep.26219] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
315 Auer MK, Stalla GK, Stieg MR. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary 2016;19:461-71. [PMID: 27194386 DOI: 10.1007/s11102-016-0726-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
316 Chen KW, Meng FC, Shih YL, Su FY, Lin YP, Lin F, Lin JW, Chang WK, Lee CJ, Li YH, Hsieh CB, Lin GM. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018;15:545. [PMID: 29562671 DOI: 10.3390/ijerph15030545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
317 Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014;63:161-7. [DOI: 10.1016/j.metabol.2013.10.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
318 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
319 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
320 Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, Kärjä V, Käkelä P, Ågren J, Tiainen M, Schwab U, Kuusisto J, Laakso M, Pihlajamäki J. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. Metabolism 2016;65:655-66. [PMID: 27085774 DOI: 10.1016/j.metabol.2016.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
321 Mikolajczyk AE, Farnan JM, Mcconville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology 2016;64:2210-8. [DOI: 10.1002/hep.28741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
322 Assimakopoulos K, Karaivazoglou K, Tsermpini EE, Diamantopoulou G, Triantos C. Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. J Psychosom Res 2018;112:73-80. [PMID: 30097139 DOI: 10.1016/j.jpsychores.2018.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
323 Lee SY, Sung JH. Gut-liver on a chip toward an in vitro model of hepatic steatosis. Biotechnol Bioeng 2018;115:2817-27. [PMID: 29981260 DOI: 10.1002/bit.26793] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
324 Claudel T, Trauner M. Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. Hepatology 2013;57:2106-9. [PMID: 23447428 DOI: 10.1002/hep.26340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
325 Armstrong T, Ly KV, Ghahremani S, Calkins KL, Wu HH. Free-breathing 3-D quantification of infant body composition and hepatic fat using a stack-of-radial magnetic resonance imaging technique. Pediatr Radiol 2019;49:876-88. [DOI: 10.1007/s00247-019-04384-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
326 Pathak S, Pandanaboyana S, Daniels I, Smart N, Prasad KR. Obesity and colorectal liver metastases: Mechanisms and management. Surg Oncol 2016;25:246-51. [PMID: 27566030 DOI: 10.1016/j.suronc.2016.05.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
327 Tomita K, Freeman BL, Bronk SF, LeBrasseur NK, White TA, Hirsova P, Ibrahim SH. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 2016;6:28786. [PMID: 27349927 DOI: 10.1038/srep28786] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
328 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Ooi GJ, Burton PR, Doyle L, Wentworth JM, Bhathal PS, Sikaris K, Cowley MA, Roberts SK, Kemp W, O’brien PE, Brown WA. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. OBES SURG 2017;27:115-25. [DOI: 10.1007/s11695-016-2246-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
330 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
331 Li CX, Wang HW, Jiang WJ, Li GC, Zhang YD, Luo CH, Li XC. The Inhibition of Aldose Reductase Accelerates Liver Regeneration through Regulating Energy Metabolism. Oxid Med Cell Longev. 2020;2020:3076131. [PMID: 32190170 DOI: 10.1155/2020/3076131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
332 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Park H, Lee SJ. Working hours and nonalcoholic fatty liver disease according to sleep duration. Chronobiol Int 2019;36:1671-80. [PMID: 31581841 DOI: 10.1080/07420528.2019.1670671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
334 Di Naso FC, Porto RR, Fillmann HS, Maggioni L, Padoin AV, Ramos RJ, Mottin CC, Bittencourt A, Marroni NA, de Bittencourt PI. Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression. Obesity (Silver Spring). 2015;23:120-129. [PMID: 25292174 DOI: 10.1002/oby.20919] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
335 Birjandi M, Ayatollahi SM, Pourahmad S, Safarpour AR. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J 2016;18:e32858. [PMID: 28191344 DOI: 10.5812/ircmj.32858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
336 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(5): 274-283 [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 20.0] [Reference Citation Analysis]
337 Hong Y, Dufendach K, Wang Y, Thoma F, Kilic A. Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. J Card Surg 2021;36:2277-83. [PMID: 33783048 DOI: 10.1111/jocs.15536] [Reference Citation Analysis]
338 Gerhard GS, Benotti P, Wood GC, Chu X, Argyropoulos G, Petrick A, Strodel WE, Gabrielsen JD, Ibele A, Still CD, Kingsley C, DiStefano J. Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity. J Obes 2014;2014:368210. [PMID: 25610640 DOI: 10.1155/2014/368210] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
339 Jaruvongvanich V, Riangwiwat T, Sanguankeo A, Upala S. Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis. Saudi J Gastroenterol 2016;22:407-14. [PMID: 27976635 DOI: 10.4103/1319-3767.195551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
340 Tanaka N, Takahashi S, Fang ZZ, Matsubara T, Krausz KW, Qu A, Gonzalez FJ. Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta. 2014;1841:1596-1607. [PMID: 25178843 DOI: 10.1016/j.bbalip.2014.08.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
341 Schumacher JD, Kong B, Pan Y, Zhan L, Sun R, Aa J, Rizzolo D, Richardson JR, Chen A, Goedken M, Aleksunes LM, Laskin DL, Guo GL. The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis. Toxicol Appl Pharmacol 2017;330:1-8. [PMID: 28673684 DOI: 10.1016/j.taap.2017.06.023] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
342 Itzel T, Neubauer M, Ebert M, Evert M, Teufel A. Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource. Sci Rep 2020;10:4760. [PMID: 32179762 DOI: 10.1038/s41598-020-61508-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel) 2021;14:995. [PMID: 34681219 DOI: 10.3390/ph14100995] [Reference Citation Analysis]
344 Duarte FO, Sene-Fiorese M, Cheik NC, Maria AS, de Aquino AE Jr, Oishi JC, Rossi EA, Garcia de Oliveira Duarte AC, Dâmaso AR. Food restriction and refeeding induces changes in lipid pathways and fat deposition in the adipose and hepatic tissues in rats with diet-induced obesity. Exp Physiol 2012;97:882-94. [PMID: 22467759 DOI: 10.1113/expphysiol.2011.064121] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
345 Ackerman Z, Skarzinski G, Grozovski M, Oron-herman M, Sela B. Effects of Antihypertensive and Triglyceride-lowering Agents on Hepatic Copper Concentrations in Rats with Fatty Liver Disease. Basic Clin Pharmacol Toxicol 2014;115:545-51. [DOI: 10.1111/bcpt.12283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
346 Gangadhar K, Chintapalli KN, Cortez G, Nair SV. MRI evaluation of fatty liver in day to day practice: Quantitative and qualitative methods. The Egyptian Journal of Radiology and Nuclear Medicine 2014;45:619-26. [DOI: 10.1016/j.ejrnm.2014.05.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
347 Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients 2021;13:3042. [PMID: 34578919 DOI: 10.3390/nu13093042] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:1028-33.e2. [PMID: 22610002 DOI: 10.1016/j.cgh.2012.05.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
349 Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice 2020;170:108487. [DOI: 10.1016/j.diabres.2020.108487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
350 Gill RM, Kakar S. Nonalcoholic Steatohepatitis. Surgical Pathology Clinics 2013;6:227-57. [DOI: 10.1016/j.path.2013.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
351 Wattacheril J, Chalasani N. Management of nonalcoholic fatty liver disease: Role of bariatric surgery. Clin Liver Dis (Hoboken) 2012;1:119-21. [PMID: 31186866 DOI: 10.1002/cld.80] [Reference Citation Analysis]
352 Freire T, Senior AM, Perks R, Pulpitel T, Clark X, Brandon AE, Wahl D, Hatchwell L, Le Couteur DG, Cooney GJ, Larance M, Simpson SJ, Solon-Biet SM. Sex-specific metabolic responses to 6 hours of fasting during the active phase in young mice. J Physiol 2020;598:2081-92. [PMID: 32198893 DOI: 10.1113/JP278806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
353 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 61] [Article Influence: 17.4] [Reference Citation Analysis]
354 Tang JT, Mao YM. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence: Pharmacotherapy of NASH. Journal of Digestive Diseases 2017;18:607-17. [DOI: 10.1111/1751-2980.12557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
355 Lauszus JS, Eriksen PL, Hansen MM, Eriksen LL, Shawcross DL, Vilstrup H, Thomsen KL, Stoy S. Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis. Clin Exp Gastroenterol 2021;14:441-9. [PMID: 34803389 DOI: 10.2147/CEG.S329424] [Reference Citation Analysis]
356 Zhou YY, Zhou XD, Wu SJ, Hu XQ, Tang B, Poucke SV, Pan XY, Wu WJ, Gu XM, Fu SW, Zheng MH. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2018;30:631-6. [PMID: 29351115 DOI: 10.1097/MEG.0000000000001075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
357 Hagström H, Nasr P, Ekstedt M, Kechagias S, Stål P, Bedossa P, Hultcrantz R. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology 2017;52:87-91. [DOI: 10.1080/00365521.2016.1230779] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
358 Manoria P, Inamdar S, Kumar R. Hepatobiliary dysfunction in Type-2 diabetes mellitus. J Family Med Prim Care 2017;6:563-7. [PMID: 29417009 DOI: 10.4103/2249-4863.222018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
359 Walker RW, Belbin GM, Sorokin EP, Van Vleck T, Wojcik GL, Moscati A, Gignoux CR, Cho J, Abul-Husn NS, Nadkarni G, Kenny EE, Loos RJF. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol 2020;72:1070-81. [PMID: 32145261 DOI: 10.1016/j.jhep.2020.01.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
360 Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:64-73. [PMID: 30430605 DOI: 10.1111/apt.15030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
361 Georgoulis M, Kontogianni MD, Margariti A, Tiniakos D, Fragopoulou E, Zafiropoulou R, Papatheodoridis G. Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease. J Hum Nutr Diet 2015;28:409-15. [PMID: 25988570 DOI: 10.1111/jhn.12323] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
362 Keramida G, Roldao Pereira L, Kaya G, Peters AM. Hepatic and splenic 18 F‐FDG blood clearance rates (Ki) in hepatic steatosis and diabetes mellitus. Clin Physiol Funct Imaging 2019;40:99-105. [DOI: 10.1111/cpf.12610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Kim JJ, Kim D, Yim JY, Kang JH, Han KH, Kim SM, Hwang KR, Ku SY, Suh CS, Kim SH, Choi YM. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45:1403-1412. [PMID: 28370150 DOI: 10.1111/apt.14058] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
364 Roeb E, Canbay A. Nichtalkoholische Fettlebererkrankungen. Gastroenterologe 2016;11:205-15. [DOI: 10.1007/s11377-016-0063-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
365 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
366 Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
367 Srivastava RAK. Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. J Diabetes Metab Disord 2018;17:381-91. [PMID: 30918873 DOI: 10.1007/s40200-018-0378-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
368 Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15532-15538 [PMID: 25400437 DOI: 10.3748/wjg.v20.i42.15532] [Cited by in CrossRef: 99] [Cited by in F6Publishing: 84] [Article Influence: 12.4] [Reference Citation Analysis]
369 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
370 Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. J Med Ultrasound 2019;27:19-25. [PMID: 31031531 DOI: 10.4103/JMU.JMU_53_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
371 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
372 Mazzoccoli G, Vinciguerra M, Oben J, Tarquini R, De Cosmo S. Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. Liver Int. 2014;34:1133-1152. [PMID: 24649929 DOI: 10.1111/liv.12534] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
373 Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22-29. [PMID: 22554256 DOI: 10.1111/j.1365-2036.2012.05121.x] [Cited by in Crossref: 226] [Cited by in F6Publishing: 203] [Article Influence: 22.6] [Reference Citation Analysis]
374 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
375 Swanson A, Geller J, DeMartini K, Fernandez A, Fehon D. Active Coping and Perceived Social Support Mediate the Relationship Between Physical Health and Resilience in Liver Transplant Candidates. J Clin Psychol Med Settings 2018;25:485-96. [PMID: 29546621 DOI: 10.1007/s10880-018-9559-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
376 Kim H, Lee K, Lee KW, Yi NJ, Lee HW, Hong G, Choi Y, You T, Suh SW, Jang JJ. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28:521-529. [PMID: 24579874 DOI: 10.1111/ctr.12343] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
377 Valva P, Rios D, Casciato P, Gadano A, Galdame O, Mullen E, Bertot G, de Matteo E, Preciado MV. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina. European Journal of Gastroenterology & Hepatology 2018;30:637-44. [DOI: 10.1097/meg.0000000000001079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
378 Tutunchi H, Ostadrahimi A, Saghafi‐asl M, Maleki V. The effects of oleoylethanolamide, an endogenous PPAR‐α agonist, on risk factors for NAFLD: A systematic review. Obesity Reviews 2019;20:1057-69. [DOI: 10.1111/obr.12853] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
379 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
380 Yu XY, Zhao Y, Song XX, Song ZY. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J Zhejiang Univ Sci B. 2014;15:879-887. [PMID: 25294377 DOI: 10.1631/jzus.b1400028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
381 Jiménez-Cortegana C, García-Galey A, Tami M, Del Pino P, Carmona I, López S, Alba G, Sánchez-Margalet V. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:762. [PMID: 34209386 DOI: 10.3390/biomedicines9070762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
382 Cai C, Lin Y, Yu C. Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2019;2019:2096161. [PMID: 31531307 DOI: 10.1155/2019/2096161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
383 Kazankov K, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. J Gastroenterol Hepatol 2015;30:1293-300. [PMID: 25772748 DOI: 10.1111/jgh.12943] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
384 Asokan SM, Wang RY, Hung TH, Lin WT. Hepato-protective effects of Glossogyne tenuifolia in Streptozotocin-nicotinamide-induced diabetic rats on high fat diet. BMC Complement Altern Med 2019;19:117. [PMID: 31170991 DOI: 10.1186/s12906-019-2529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
385 Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Dig Liver Dis 2012;44:935-9. [PMID: 22809960 DOI: 10.1016/j.dld.2012.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
386 Park HE, Lee H, Choi S, Kwak M, Yang JI, Yim JY, Chung GE. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol 2019;54:271-80. [DOI: 10.1007/s00535-018-1516-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
387 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
388 Bouzianas DG, Bouziana SD, Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev. 2013;71:753-771. [PMID: 24148001 DOI: 10.1111/nure.12073] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
389 Sun S, Wu T, Wang M, Li W, Wang L, He S, Wei H, Song H, Ji G. The association between TCM syndromes and SCAP polymorphisms in subjects with non-alcoholic fatty liver disease. European Journal of Integrative Medicine 2013;5:386-92. [DOI: 10.1016/j.eujim.2013.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
390 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
391 Milic S, Štimac D. Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. Dig Dis 2012;30:158-62. [DOI: 10.1159/000336669] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 12.4] [Reference Citation Analysis]
392 Kouzu K, Tsujimoto H, Nishikawa M, Harada M, Sugihara T, Nagata H, Hiraki S, Yaguchi Y, Takahata R, Nomura S, Ito N, Ishibashi Y, Itazaki Y, Tsuchiya S, Hase K, Kishi Y, Ueno H. Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer. Gastric Cancer 2020;23:356-62. [DOI: 10.1007/s10120-019-01009-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
393 Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2015; 7(16): 2041-2052 [PMID: 26261693 DOI: 10.4254/wjh.v7.i16.2041] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
394 Tamada H, Naito H, Kitamori K, Hayashi Y, Yamagishi N, Kato M, Nakajima T. Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats. PLoS One 2016;11:e0145939. [PMID: 26727365 DOI: 10.1371/journal.pone.0145939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
395 Owada Y, Tamura T, Tanoi T, Ozawa Y, Shimizu Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S. Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. Pathol Int. 2018;68:12-22. [PMID: 29154469 DOI: 10.1111/pin.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
396 Honda Y, Imajo K, Kobayashi T, Kessoku T, Ogawa Y, Tomeno W, Yoneda M, Kobayashi N, Saito S, Nakajima A. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2019;49:1136-46. [PMID: 31144415 DOI: 10.1111/hepr.13382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
397 Verna EC, Loomba R. Editorial: Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther 2015;41:492-3. [PMID: 25631653 DOI: 10.1111/apt.13075] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
398 Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon 2015;15:e24449. [PMID: 25741373 DOI: 10.5812/hepatmon.24449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
399 Kozyra M, Johansson I, Nordling Å, Ullah S, Lauschke VM, Ingelman-Sundberg M. Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Sci Rep 2018;8:14297. [PMID: 30250238 DOI: 10.1038/s41598-018-32722-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
400 Ogawa Y, Honda Y, Kessoku T, Tomeno W, Imajo K, Yoneda M, Kawanaka M, Kirikoshi H, Ono M, Taguri M, Saito S, Yamanaka T, Wada K, Nakajima A. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33:1795-1803. [PMID: 29633352 DOI: 10.1111/jgh.14156] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
401 Chen J, Wang W, Qi Y, Kaczorowski D, McCaughan GW, Gamble JR, Don AS, Gao X, Vadas MA, Xia P. Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγ. Biochim Biophys Acta 2016;1861:138-47. [PMID: 26615875 DOI: 10.1016/j.bbalip.2015.11.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
402 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
403 Wang J, Zhu W, Huang S, Xu L, Miao M, Wu C, Yu C, Li Y, Xu C. Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: A 7-year prospective study. Liver Int 2017;37:1202-8. [PMID: 28106941 DOI: 10.1111/liv.13363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
404 Wu Z, Cheng Z, Yi Z, Xie M, Zeng H, Lu L, Xu X, Shen J. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast‐Enhanced MRI. J Magn Reson Imaging 2017;45:1485-93. [DOI: 10.1002/jmri.25455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
405 Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016;61:2389-2396. [PMID: 26993825 DOI: 10.1007/s10620-016-4125-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
406 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
407 Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol. 2018;98:82-89. [PMID: 29279175 DOI: 10.1016/j.ejrad.2017.11.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
408 Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, Yu X. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2017;27:63-9. [PMID: 27956025 DOI: 10.1016/j.numecd.2016.10.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
409 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
410 Baratta F, Pastori D, Del Ben M, Polimeni L, Labbadia G, Di Santo S, Piemonte F, Tozzi G, Violi F, Angelico F. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. EBioMedicine. 2015;2:750-754. [PMID: 26288848 DOI: 10.1016/j.ebiom.2015.05.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
411 Suzuki R, Brown GA, Christopher JA, Scully CCG, Congreve M. Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. J Med Chem 2020;63:905-27. [PMID: 31577440 DOI: 10.1021/acs.jmedchem.9b00835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
412 Long MT, Pedley A, Massaro JM, Hoffmann U, Fox CS. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One 2016;11:e0157517. [PMID: 27341207 DOI: 10.1371/journal.pone.0157517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
413 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
414 Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017;5:216-223. [PMID: 28936403 DOI: 10.14218/jcth.2016.00068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
415 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
416 Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res 2018;46:4447-54. [PMID: 30185098 DOI: 10.1177/0300060518793039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
417 Aragonès G, Auguet T, Armengol S, Berlanga A, Guiu-Jurado E, Aguilar C, Martínez S, Sabench F, Porras JA, Ruiz MD, Hernández M, Sirvent JJ, Del Castillo D, Richart C. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E630. [PMID: 27128907 DOI: 10.3390/ijms17050630] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
418 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
419 Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69:1155-1163. [PMID: 30290973 DOI: 10.1016/j.jhep.2018.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
420 Hashemian M, Merat S, Poustchi H, Jafari E, Radmard AR, Kamangar F, Freedman N, Hekmatdoost A, Sheikh M, Boffetta P, Sinha R, Dawsey SM, Abnet CC, Malekzadeh R, Etemadi A. Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study. Am J Gastroenterol 2021;116:1667-75. [PMID: 33767101 DOI: 10.14309/ajg.0000000000001229] [Reference Citation Analysis]
421 Wang S, Tong B, Zhang HL, Jiang XZ, Zhang J, Duan HL, Wu SL. Relationship between waist circumference level and new onset of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2015; 23(20): 3219-3225 [DOI: 10.11569/wcjd.v23.i20.3219] [Reference Citation Analysis]
422 Aroner SA, Mukamal KJ, St-Jules DE, Budoff MJ, Katz R, Criqui MH, Allison MA, de Boer IH, Siscovick DS, Ix JH, Jensen MK. Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2017;185:54-64. [PMID: 27856445 DOI: 10.1093/aje/kww095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
423 Hernández-Conde M, Llop E, Fernández Carrillo C, Tormo B, Abad J, Rodriguez L, Perelló C, López Gomez M, Martínez-Porras JL, Fernández Puga N, Trapero-Marugan M, Fraga E, Ferre Aracil C, Calleja Panero JL. Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(42): 6658-6668 [PMID: 33268953 DOI: 10.3748/wjg.v26.i42.6658] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Liava C, Sinakos E. Semaglutide for nonalcoholic steatohepatitis: closer to a solution? Hepatobiliary Surg Nutr 2021;10:541-4. [PMID: 34430539 DOI: 10.21037/hbsn-21-231] [Reference Citation Analysis]
425 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
426 Wang BF, Wang Y, Ao R, Tong J, Wang BY. AdipoQ T45 G and G276 T Polymorphisms and Susceptibility to Nonalcoholic Fatty Liver Disease Among Asian Populations: A Meta-Analysis and Meta-Regression. J Clin Lab Anal 2016;30:47-57. [PMID: 25385252 DOI: 10.1002/jcla.21814] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
427 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
428 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
429 Albhaisi SAM, Sanyal AJ. New drugs for NASH. Liver Int 2021;41 Suppl 1:112-8. [PMID: 34155794 DOI: 10.1111/liv.14844] [Reference Citation Analysis]
430 Wu Z, Yang F, Jiang S, Sun X, Xu J. Induction of Liver Steatosis in BAP31-Deficient Mice Burdened with Tunicamycin-Induced Endoplasmic Reticulum Stress. Int J Mol Sci 2018;19:E2291. [PMID: 30081561 DOI: 10.3390/ijms19082291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
431 Koretz RL. JPEN Journal Club 25. Study Design. JPEN J Parenter Enteral Nutr 2017;41:263-5. [PMID: 28135159 DOI: 10.1177/0148607116679787] [Reference Citation Analysis]
432 Parikh P, Phadke A, Sawant P. Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India. Indian J Gastroenterol 2015;34:169-73. [PMID: 25875369 DOI: 10.1007/s12664-015-0541-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
433 Wang Y, Zhu Y, Niu J, Deng Q, Guo S, Jiang H, Peng Z, Xue Y, Peng H, Xuan L, Pan G. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol 2020;404:115169. [PMID: 32738331 DOI: 10.1016/j.taap.2020.115169] [Reference Citation Analysis]
434 Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M, Haufe W, Hooker C, Richards L, Sirlin CB, Loomba R. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2016;9:692-701. [PMID: 27582882 DOI: 10.1177/1756283X16656735] [Cited by in Crossref: 80] [Cited by in F6Publishing: 40] [Article Influence: 13.3] [Reference Citation Analysis]
435 Zhang WY, Piao XX, Jin HY, Li CH, Jin AH, Han HM. Protective effect of boschniakia rossica ethanol extract on nonalcoholic fatty liver disease in rats and mechanisms involved. Shijie Huaren Xiaohua Zazhi 2012; 20(32): 3087-3094 [DOI: 10.11569/wcjd.v20.i32.3087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Noorian S, Jeon Y, Nguyen MT, Sauk J, Limketkai BN. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflamm Bowel Dis 2021:izab199. [PMID: 34374782 DOI: 10.1093/ibd/izab199] [Reference Citation Analysis]
437 Zhu JZ, Hollis-Hansen K, Wan XY, Fei SJ, Pang XL, Meng FD, Yu CH, Li YM. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. World J Gastroenterol 2016; 22(36): 8226-8233 [PMID: 27688665 DOI: 10.3748/wjg.v22.i36.8226] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
438 Van Nieuwenhove T, Rasschaert G, Kharagjitsingh A, Keymeulen B, Reynaert H, Kindt S. The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study. Acta Gastroenterol Belg 2021;84:541-7. [PMID: 34965034 DOI: 10.51821/84.4.003] [Reference Citation Analysis]
439 Yamasaki Y, Nouso K, Miyahara K, Wada N, Dohi C, Morimoto Y, Kinugasa H, Takeuchi Y, Yasunaka T, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Amano M, Nishimura S, Yamamoto K. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis: Glycan markers for fatty liver diseases. J Gastroenterol Hepatol 2015;30:528-34. [DOI: 10.1111/jgh.12726] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
440 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Reference Citation Analysis]
441 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
442 Moore MP, Cunningham RP, Davis RAH, Deemer SE, Roberts BM, Plaisance EP, Rector RS. A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G564-72. [PMID: 33501889 DOI: 10.1152/ajpgi.00259.2020] [Reference Citation Analysis]
443 Singh RG, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism. 2017;69:1-13. [PMID: 28285638 DOI: 10.1016/j.metabol.2016.12.012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 13.8] [Reference Citation Analysis]
444 Singh A, Gosai F, Siddiqui MT, Gupta M, Lopez R, Lawitz E, Poordad F, Carey W, McCullough A, Alkhouri N. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol 2020;54:891-7. [PMID: 32168133 DOI: 10.1097/MCG.0000000000001339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
445 Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13:2062-2070. [PMID: 26226097 DOI: 10.1016/j.cgh.2015.07.029] [Cited by in Crossref: 159] [Cited by in F6Publishing: 137] [Article Influence: 22.7] [Reference Citation Analysis]
446 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
447 Zou RC, Li LL, Yuan HL. Current Status of Research on the Role of Circular RNAs in Hepatocellular Carcinoma and Clinical Implications. Med Sci Monit 2020;26:e923832. [PMID: 32779638 DOI: 10.12659/MSM.923832] [Reference Citation Analysis]
448 Lin SZ, Chen YW, Fan JG. Non‐alcoholic fatty liver disease to metabolic dysfunction‐associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. J Dig Dis 2020;21:604-9. [DOI: 10.1111/1751-2980.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
449 Şerban RC, Scridon A. Data Linking Diabetes Mellitus and Atrial Fibrillation-How Strong Is the Evidence? From Epidemiology and Pathophysiology to Therapeutic Implications. Can J Cardiol 2018;34:1492-502. [PMID: 30404752 DOI: 10.1016/j.cjca.2018.08.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
450 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. Am J Med 2021;134:23-9. [PMID: 32931760 DOI: 10.1016/j.amjmed.2020.08.010] [Reference Citation Analysis]
451 Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes 2016;9:157. [PMID: 26969270 DOI: 10.1186/s13104-016-1946-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
452 Kiziltas S, Ata P, Colak Y, Mesçi B, Senates E, Enc F, Ulasoglu C, Tuncer I, Oguz A. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab Syndr Relat Disord. 2014;12:165-170. [PMID: 24443993 DOI: 10.1089/met.2013.0120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
453 Cunningham RP, Moore MP, Meers GM, Ruegsegger GN, Booth FW, Rector RS. Maternal Physical Activity and Sex Impact Markers of Hepatic Mitochondrial Health. Medicine & Science in Sports & Exercise 2018;50:2040-8. [DOI: 10.1249/mss.0000000000001675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
455 Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:404-14. [PMID: 33948067 DOI: 10.20524/aog.2021.0604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
456 Lee YW, Yarrington CD. Obstetric Outcomes in Women with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 2017;15:387-92. [DOI: 10.1089/met.2017.0058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
457 Meng G, Zhang B, Yu F, Li C, Zhang Q, Liu L, Wu H, Xia Y, Bao X, Shi H, Su Q, Gu Y, Fang L, Yang H, Yu B, Sun S, Wang X, Zhou M, Jia Q, Jiao H, Wang B, Guo Q, Carvalhoa LA, Sun Z, Song K, Yu M, Niu K. Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population. Eur J Nutr 2018;57:2113-21. [PMID: 28702720 DOI: 10.1007/s00394-017-1485-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
458 Kang Y, Zhang X, Cai Y, Su J, Kong X. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Reviews in Medical Microbiology 2016;27:141-52. [DOI: 10.1097/mrm.0000000000000085] [Cited by in Crossref: 11] [Article Influence: 1.8] [Reference Citation Analysis]
459 Abbasi-Ghahramanloo A, Moshiri E, Afrashteh S, Gholami A, Safiri S, Mohammadbeigi A, Ansari H. Comorbidity of metabolic syndrome components in a population-based screening program: A latent class analysis. Med J Islam Repub Iran 2020;34:69. [PMID: 32974235 DOI: 10.34171/mjiri.34.69] [Reference Citation Analysis]
460 Moon SW, Kim SY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Ro JS, Lee YH, Lee SH. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010. Int J Chron Obstruct Pulmon Dis 2018;13:2603-11. [PMID: 30214178 DOI: 10.2147/COPD.S166902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
461 Kurinami N, Sugiyama S, Yoshida A, Hieshima K, Miyamoto F, Kajiwara K, Jinnouch K, Jinnouchi T, Jinnouchi H. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2018;142:254-63. [DOI: 10.1016/j.diabres.2018.05.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
462 Narankiewicz D, Ruiz-Nava J, Buonaiuto V, Ruiz-Moreno MI, López-Carmona MD, Pérez-Belmonte LM, Gómez-Huelgas R, Bernal-López MR. Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population. Int J Environ Res Public Health 2020;17:E3518. [PMID: 32443453 DOI: 10.3390/ijerph17103518] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
463 Albaugh VL, Banan B, Ajouz H, Abumrad NN, Flynn CR. Bile acids and bariatric surgery. Mol Aspects Med 2017;56:75-89. [PMID: 28390813 DOI: 10.1016/j.mam.2017.04.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
464 Principi M, Iannone A, Losurdo G, Mangia M, Shahini E, Albano F, Rizzi SF, La Fortezza RF, Lovero R, Contaldo A, Barone M, Leandro G, Ierardi E, Di Leo A. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018;24:1589-1596. [PMID: 29688336 DOI: 10.1093/ibd/izy051] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
465 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 31.0] [Reference Citation Analysis]
466 Xu C, Markova M, Seebeck N, Loft A, Hornemann S, Gantert T, Kabisch S, Herz K, Loske J, Ost M, Coleman V, Klauschen F, Rosenthal A, Lange V, Machann J, Klaus S, Grune T, Herzig S, Pivovarova-Ramich O, Pfeiffer AFH. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. Liver Int 2020;40:2982-97. [PMID: 32652799 DOI: 10.1111/liv.14596] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
467 Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, Kanth R, Gayam V. Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease. Cureus 2018;10:e3626. [PMID: 30697502 DOI: 10.7759/cureus.3626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
468 Chen X, Fu XS, Li CP, Zhao HX. ER stress and ER stress-induced apoptosis are activated in gastric SMCs in diabetic rats. World J Gastroenterol 2014; 20(25): 8260-8267 [PMID: 25009401 DOI: 10.3748/wjg.v20.i25.8260] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
469 Hurr C, Simonyan H, Morgan DA, Rahmouni K, Young CN. Liver sympathetic denervation reverses obesity-induced hepatic steatosis. J Physiol 2019;597:4565-80. [PMID: 31278754 DOI: 10.1113/JP277994] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
470 Green CJ, Hodson L. The influence of dietary fat on liver fat accumulation. Nutrients 2014;6:5018-33. [PMID: 25389901 DOI: 10.3390/nu6115018] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
471 Patel V, Sanyal AJ, Sterling R. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016;20:277-292. [PMID: 27063269 DOI: 10.1016/j.cld.2015.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
472 Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol 2013;2013:583786. [PMID: 23476808 DOI: 10.1155/2013/583786] [Cited by in Crossref: 24] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
473 Folini L, Veronelli A, Benetti A, Pozzato C, Cappelletti M, Masci E, Micheletto G, Pontiroli AE. Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. Acta Diabetol. 2014;51:361-368. [PMID: 24085682 DOI: 10.1007/s00592-013-0516-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
474 Chung GE, Choi SY, Kim D, Kwak MS, Park HE, Kim MK, Yim JY. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index. Medicine (Baltimore). 2015;94:e654. [PMID: 25816034 DOI: 10.1097/md.0000000000000654] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
475 Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, de Oliveira CP, Andraus W, Alves VA. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106-125. [PMID: 26073454 DOI: 10.1016/j.plipres.2015.05.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
476 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
477 Tappy L, Lê KA. Does fructose consumption contribute to non-alcoholic fatty liver disease? Clin Res Hepatol Gastroenterol 2012;36:554-60. [PMID: 22795319 DOI: 10.1016/j.clinre.2012.06.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
478 Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, Christian R. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity (Silver Spring). 2019;27:41-49. [PMID: 30520566 DOI: 10.1002/oby.22344] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 19.5] [Reference Citation Analysis]
479 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
480 Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, Harrison SA. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293-300. [PMID: 25521607 DOI: 10.1111/apt.13042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
481 Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. Clin Nutr 2020;39:3533-62. [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
482 Pu Y, Xiang J, Zhang X, Deng Y, Liu H, Tan W. CD36 as a Molecular Target of Functional DNA Aptamer NAFLD01 Selected against NAFLD Cells. Anal Chem 2021;93:3951-8. [PMID: 33596054 DOI: 10.1021/acs.analchem.0c04866] [Reference Citation Analysis]
483 Zhang Y, He H, Zeng YP, Yang LD, Jia D, An ZM, Jia WG. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. Lipids Health Dis 2020;19:134. [PMID: 32527258 DOI: 10.1186/s12944-020-01310-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
484 Garduno A, Wu T. Tobacco Smoke and CYP1A2 Activity in a US Population with Normal Liver Enzyme Levels. Int J Environ Res Public Health 2021;18:2225. [PMID: 33668222 DOI: 10.3390/ijerph18052225] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Hu S, Xia L, Luo H, Xu Y, Yu H, Xu D, Wang H. Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway. Toxicology 2019;417:23-34. [PMID: 30776459 DOI: 10.1016/j.tox.2019.02.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
486 Javanmardi MA, Mohammad Shahi M, Seyedian SS, Haghighizadeh MH. Effects of Phytosterol Supplementation on Serum Levels of Lipid Profiles, Liver Enzymes, Inflammatory Markers, Adiponectin, and Leptin in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr 2018;:1-8. [PMID: 29768109 DOI: 10.1080/07315724.2018.1466739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
487 Li AA, Ahmed A, Kim D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver. 2020;14:168-178. [PMID: 31195434 DOI: 10.5009/gnl19069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
488 Lin YC, Lian IB, Kor CT, Chang CC, Su PY, Chang WT, Liang YF, Su WW, Soon MS. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. BMJ Open 2017;7:e014215. [PMID: 28115335 DOI: 10.1136/bmjopen-2016-014215] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
489 Pereira RR, de Abreu IC, Guerra JF, Lage NN, Lopes JM, Silva M, de Lima WG, Silva ME, Pedrosa ML. Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. Oxid Med Cell Longev 2016;2016:8379105. [PMID: 27642496 DOI: 10.1155/2016/8379105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
490 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
491 Macut D, Božić-Antić I, Bjekić-Macut J, Tziomalos K. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol 2017;177:R145-58. [PMID: 28694246 DOI: 10.1530/EJE-16-1063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
492 Paglialunga S, Dehn CA. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. Lipids Health Dis. 2016;15:159. [PMID: 27640119 DOI: 10.1186/s12944-016-0321-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
493 Song JU, Jang Y, Lim SY, Ryu S, Song WJ, Byrne CD, Sung KC. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. PLoS One 2019;14:e0208736. [PMID: 30673698 DOI: 10.1371/journal.pone.0208736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
494 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
495 Zhang C, Yuan W, Fang J, Wang W, He P, Lei J, Wang C. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. PLoS One 2016;11:e0161792. [PMID: 27560482 DOI: 10.1371/journal.pone.0161792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
496 Voloshin I, Hahn-Obercyger M, Anavi S, Tirosh O. L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease. Lipids Health Dis 2014;13:69. [PMID: 24750587 DOI: 10.1186/1476-511X-13-69] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
497 Hedderich DM, Hasenberg T, Haneder S, Schoenberg SO, Kücükoglu Ö, Canbay A, Otto M. Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction. OBES SURG 2017;27:1755-62. [DOI: 10.1007/s11695-016-2531-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
498 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
499 Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol 2015;1:646-663.e4. [PMID: 26783552 DOI: 10.1016/j.jcmgh.2015.07.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 11.7] [Reference Citation Analysis]
500 Zhou J, Long Y, Ding N, Su Y. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109195] [Reference Citation Analysis]
501 Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134-143. [PMID: 23718573 DOI: 10.1111/apt.12352] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 12.6] [Reference Citation Analysis]
502 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
503 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365. [PMID: 23175136 DOI: 10.1002/hep.26156] [Cited by in Crossref: 410] [Cited by in F6Publishing: 382] [Article Influence: 45.6] [Reference Citation Analysis]
504 Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Fallahzadeh MK, Maharlouei N, Babaeinejad M, Mehravar S. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13:e9248. [PMID: 23922564 DOI: 10.5812/hepatmon.9248] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
505 Godin O, Leboyer M, Belzeaux R, Bellivier F, Loftus J, Courtet P, Dubertret C, Gard S, Henry C, Llorca PM, Schwan R, Passerieux C, Polosan M, Samalin L, Olié E, Etain B; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand 2021;143:82-91. [PMID: 33011976 DOI: 10.1111/acps.13239] [Reference Citation Analysis]
506 Macías J, Mancebo M, Merino D, Téllez F, Montes-Ramírez ML, Pulido F, Rivero-Juárez A, Raffo M, Pérez-Pérez M, Merchante N, Cotarelo M, Pineda JA; Spanish AIDS Research Network-HEP09 Study Group. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. Clin Infect Dis 2017;65:1012-9. [PMID: 28903510 DOI: 10.1093/cid/cix467] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
507 Sharma H, Estep M, Birerdinc A, Afendy A, Moazzez A, Elariny H, Goodman Z, Chandhoke V, Baranova A, Younossi ZM. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013;28:1410-1415. [PMID: 23663110 DOI: 10.1111/jgh.12268] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
508 Mir HM, Stepanova M, Afendy H, Cable R, Younossi ZM. Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. J Clin Exp Hepatol. 2013;3:181-185. [PMID: 25755498 DOI: 10.1016/j.jceh.2013.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
509 Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:1555-1560. [PMID: 22741595 DOI: 10.1111/j.1440-1746.2012.07222.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 117] [Article Influence: 13.0] [Reference Citation Analysis]
510 Chen C, Zhu Z, Mao Y, Xu Y, Du J, Tang X, Cao H. HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. Biosci Rep 2020;40:BSR20193996. [PMID: 31940026 DOI: 10.1042/BSR20193996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
511 Yzydorczyk C, Li N, Rigal E, Chehade H, Mosig D, Armengaud JB, Rolle T, Krishnasamy A, Orozco E, Siddeek B, Juvet C, Vergely C, Simeoni U. Calorie Restriction in Adulthood Reduces Hepatic Disorders Induced by Transient Postnatal Overfeeding in Mice. Nutrients 2019;11:E2796. [PMID: 31744052 DOI: 10.3390/nu11112796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
512 Arias-Loste MT, Fábrega E, López-Hoyos M, Crespo J. The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int 2015;2015:319745. [PMID: 26491664 DOI: 10.1155/2015/319745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
513 Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K, Harrison SA. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol 2016;9:4-12. [PMID: 26770262 DOI: 10.1177/1756283X15611581] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
514 Adejumo AC, Alliu S, Ajayi TO, Adejumo KL, Adegbala OM, Onyeakusi NE, Akinjero AM, Durojaiye M, Bukong TN. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS One. 2017;12:e0176416. [PMID: 28441459 DOI: 10.1371/journal.pone.0176416] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
515 Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:833-49. [PMID: 25099546 DOI: 10.3945/ajcn.114.086314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 15.8] [Reference Citation Analysis]
516 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
517 Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int J Obes (Lond) 2017;41:1207-13. [PMID: 28461687 DOI: 10.1038/ijo.2017.102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
518 Audsley J, Sasadeusz J, Lewin SR. Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV 2019;6:e808-9. [PMID: 31611037 DOI: 10.1016/S2352-3018(19)30331-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
519 García Díaz E, Guagnozzi D, Gutiérrez V, Mendoza C, Maza C, Larrañaga Y, Perdomo D, Godoy T, Taleb G. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinol Nutr 2016;63:194-201. [PMID: 26976710 DOI: 10.1016/j.endonu.2016.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
520 Eshraghian A, Iravani S, Azimzadeh P. The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity. Middle East J Dig Dis 2018;10:96-104. [PMID: 30013758 DOI: 10.15171/mejdd.2018.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
521 Gong X, Li-han, Yang Q, Yan H, Zhang Y, Li Y, Xu Y, Wang H, Zhang J, Lin C. Effects of Soothing Liver and Invigorating Spleen Recipe on Lipid Metabolism Disorders in Kupffer Cells of NAFLD Rats by LXRα/SREBP-1c Signal Pathway. Chinese Herbal Medicines 2014;6:297-304. [DOI: 10.1016/s1674-6384(14)60045-9] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
522 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
523 Kim JW, Lee YS, Park YS, Kim BH, Lee SY, Yeon JE, Lee CH. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. Sci Rep 2020;10:2671. [PMID: 32060386 DOI: 10.1038/s41598-020-59601-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
524 Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, Kim KW, Yu E, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666-1672. [PMID: 25974139 DOI: 10.1111/jgh.12996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
525 Clerx E, Kupfer SS, Leffler DA. Disparities Among Gastrointestinal Disorders in Research Funding From the National Institutes of Health. Gastroenterology 2017;153:877-80. [DOI: 10.1053/j.gastro.2017.08.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
526 Eshraghian A, Nikeghbalian S, Geramizadeh B, Malek-Hosseini SA. Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis. United European Gastroenterol J. 2018;6:97-103. [PMID: 29435319 DOI: 10.1177/2050640617707863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
527 Cai Q, Chen F, Xu F, Wang K, Zhang K, Li G, Chen J, Deng H, He Q. Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α8-mediated activation of RhoA signaling pathway. Metabolism 2020;104:154140. [PMID: 31926204 DOI: 10.1016/j.metabol.2020.154140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
528 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
529 Udompap P, Kim D, Kim WR. Current and Future Burden of Chronic Nonmalignant Liver Disease. Clin Gastroenterol Hepatol. 2015;13:2031-2041. [PMID: 26291665 DOI: 10.1016/j.cgh.2015.08.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
530 Aykut UE, Akyuz U, Yesil A, Eren F, Gerin F, Ergelen R, Celikel CA, Yilmaz Y. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand J Gastroenterol 2014;49:1343-8. [PMID: 25259621 DOI: 10.3109/00365521.2014.958099] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
531 Cruz-ramón V, Chinchilla-lópez P, Ramírez-pérez O, Méndez-sánchez N. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances. Annals of Hepatology 2017;16:S58-67. [DOI: 10.5604/01.3001.0010.5498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
532 Chou YT, Li CH, Sun ZJ, Shen WC, Yang YC, Lu FH, Chang CJ, Wu JS. A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. Nutrients 2021;13:914. [PMID: 33799865 DOI: 10.3390/nu13030914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
533 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6(5): 263-273 [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 9.6] [Reference Citation Analysis]
534 Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y. Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci. 2016;17:465. [PMID: 27043533 DOI: 10.3390/ijms17040465] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
535 Harris R, West J, Morling JR. Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Aliment Pharmacol Ther 2020;51:1199-200. [PMID: 32424922 DOI: 10.1111/apt.15714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
536 Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatology 2021. [PMID: 33811766 DOI: 10.1002/hep.31845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
537 Liu Y, She W, Wang F, Li J, Wang J, Jiang W. 3, 3'-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance. Int Immunopharmacol. 2014;23:489-498. [PMID: 25281898 DOI: 10.1016/j.intimp.2014.09.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
538 Lian C, Zhai Z, Li Z, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chemico-Biological Interactions 2020;330:109199. [DOI: 10.1016/j.cbi.2020.109199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
539 Naik A, Belič A, Zanger UM, Rozman D. Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet 2013;4:2. [PMID: 23346097 DOI: 10.3389/fgene.2013.00002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
540 Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016;51:456-64. [PMID: 26784973 DOI: 10.3109/00365521.2015.1107620] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 12.2] [Reference Citation Analysis]
541 Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci 2016;61:905-12. [PMID: 26462489 DOI: 10.1007/s10620-015-3916-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
542 Chiu CC, Huang CY, Chen TY, Kao SH, Liu JY, Wang YW, Tzang BS, Hsu TC. Beneficial Effects of Ocimum gratissimum Aqueous Extract on Rats with CCl(4)-Induced Acute Liver Injury. Evid Based Complement Alternat Med 2012;2012:736752. [PMID: 22792126 DOI: 10.1155/2012/736752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
543 Toita R, Kang JH. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease. Toxicol Lett 2020;332:1-6. [PMID: 32579995 DOI: 10.1016/j.toxlet.2020.06.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
544 Le Page A, Khalil A, Vermette P, Frost EH, Larbi A, Witkowski JM, Fulop T. The role of elastin-derived peptides in human physiology and diseases. Matrix Biol 2019;84:81-96. [PMID: 31295577 DOI: 10.1016/j.matbio.2019.07.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
545 Karlsson Sundbaum J, Eriksson N, Hallberg P, Lehto N, Wadelius M, Baecklund E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. Int J Rheum Dis 2019;22:1226-32. [PMID: 31012257 DOI: 10.1111/1756-185X.13576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
546 Sánchez-Calvo B, Cassina A, Mastrogiovanni M, Santos M, Trias E, Kelley EE, Rubbo H, Trostchansky A. Olive oil-derived nitro-fatty acids: protection of mitochondrial function in non-alcoholic fatty liver disease. J Nutr Biochem 2021;94:108646. [PMID: 33838229 DOI: 10.1016/j.jnutbio.2021.108646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Toshikuni N, Fukumura A, Hayashi N, Nomura T, Tsuchishima M, Arisawa T, Tsutsumi M. Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. J Clin Biochem Nutr. 2013;52:82-88. [PMID: 23341703 DOI: 10.3164/jcbn.12-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
548 Iwasaki T, Hirose A, Azuma T, Ohashi T, Watanabe K, Obora A, Deguchi F, Kojima T, Isozaki A, Tomofuji T. Correlation between ultrasound-diagnosed non-alcoholic fatty liver and periodontal condition in a cross-sectional study in Japan. Sci Rep 2018;8:7496. [PMID: 29760403 DOI: 10.1038/s41598-018-25857-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
549 Lebeau PF, Byun JH, Platko K, Al-Hashimi AA, Lhoták Š, MacDonald ME, Mejia-Benitez A, Prat A, Igdoura SA, Trigatti B, Maclean KN, Seidah NG, Austin RC. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep 2019;1:418-29. [PMID: 32039393 DOI: 10.1016/j.jhepr.2019.10.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
550 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
551 Pihlajamäki J, Kuulasmaa T, Kaminska D, Simonen M, Kärjä V, Grönlund S, Käkelä P, Pääkkönen M, Kainulainen S, Punnonen K. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012;56:663-670. [PMID: 22027586 DOI: 10.1016/j.jhep.2011.10.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
552 Braud L, Battault S, Meyer G, Nascimento A, Gaillard S, de Sousa G, Rahmani R, Riva C, Armand M, Maixent J, Reboul C. Antioxidant properties of tea blunt ROS-dependent lipogenesis: beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model. The Journal of Nutritional Biochemistry 2017;40:95-104. [DOI: 10.1016/j.jnutbio.2016.10.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
553 Cruz JF, Cruz MA, Machado Neto J, de Santana DS, Oliveira CC, Lima SO. Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE. Radiol Bras. 2016;49:1-5. [PMID: 26929453 DOI: 10.1590/0100-3984.2014.0124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
554 Wang J, Dong F, Su H, Zhu L, Shao S, Wu J, Liu H. H. pylori is related to NAFLD but only in female: A Cross-sectional Study. Int J Med Sci 2021;18:2303-11. [PMID: 33967606 DOI: 10.7150/ijms.50748] [Reference Citation Analysis]
555 Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Friedman SL, Diago M, Romero-Gomez M. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63:1875-1887. [PMID: 26849287 DOI: 10.1002/hep.28484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
556 Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37:392-400. [PMID: 23278163 DOI: 10.1111/apt.12186] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 11.3] [Reference Citation Analysis]
557 Oral A, Sahin T, Turker F, Kocak E. Evaluation of Plateletcrit and Platelet Distribution Width in Patients with Non-Alcoholic Fatty Liver Disease: A Retrospective Chart Review Study. Med Sci Monit 2019;25:9882-6. [PMID: 31868169 DOI: 10.12659/MSM.920172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
558 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
559 Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int. 2018;17:45-48. [PMID: 29428103 DOI: 10.1016/j.hbpd.2018.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
560 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2:633-6. [PMID: 25054002 DOI: 10.3892/br.2014.309] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
561 Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-järvinen H, Ala-korpela M, Pihlajamäki J. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int 2015;35:1853-61. [DOI: 10.1111/liv.12769] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
562 Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020;77:18-24. [PMID: 32507608 DOI: 10.1016/j.ejim.2020.05.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
563 Schmitz SM, Kroh A, Ulmer TF, Andruszkow J, Luedde T, Brozat JF, Neumann UP, Alizai PH. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems. BMC Gastroenterol 2020;20:254. [PMID: 32758151 DOI: 10.1186/s12876-020-01400-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
564 Cunningham RP, Moore MP, Moore AN, Healy JC, Roberts MD, Rector RS, Martin JS. Curcumin supplementation mitigates NASH development and progression in female Wistar rats. Physiol Rep 2018;6:e13789. [PMID: 30009570 DOI: 10.14814/phy2.13789] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
565 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
566 Wáng YXJ, Wang X, Wu P, Wang Y, Chen W, Chen H, Li J. Topics on quantitative liver magnetic resonance imaging. Quant Imaging Med Surg 2019;9:1840-90. [PMID: 31867237 DOI: 10.21037/qims.2019.09.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
567 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
568 Papandreou C, Bullò M, Tinahones FJ, Martínez-González MÁ, Corella D, Fragkiadakis GA, López-Miranda J, Estruch R, Fitó M, Salas-Salvadó J. Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutr Metab (Lond) 2017;14:58. [PMID: 28878811 DOI: 10.1186/s12986-017-0213-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
569 Takahashi Y. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci. 2017;18. [PMID: 28678199 DOI: 10.3390/ijms18071447] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 14.8] [Reference Citation Analysis]
570 Kučera O, Al-Dury S, Lotková H, Roušar T, Rychtrmoc D, Červinková Z. Steatotic rat hepatocytes in primary culture are more susceptible to the acute toxic effect of acetaminophen. Physiol Res 2012;61:S93-101. [PMID: 23130907 DOI: 10.33549/physiolres.932395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
571 Zhou Y, Lai C, Peng C, Chen M, Li B, Wang X, Sun J, Sun C. Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis. Postepy Kardiol Interwencyjnej 2017;13:250-7. [PMID: 29056998 DOI: 10.5114/aic.2017.70198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
572 Li B, Wang L, Lu Q, Da W. Liver injury attenuation by curcumin in a rat NASH model: an Nrf2 activation-mediated effect? Ir J Med Sci. 2016;185:93-100. [PMID: 25385666 DOI: 10.1007/s11845-014-1226-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
573 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
574 Younossi ZM, Stepanova M, Lawitz E, Charlton M, Loomba R, Myers RP, Subramanian M, Mchutchison JG, Goodman Z. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int 2018;38:1849-59. [DOI: 10.1111/liv.13706] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
575 Haidari F, Hojhabrimanesh A, Helli B, Seyedian SS, Ahmadi-Angali K, Abiri B. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial. BMC Gastroenterol 2020;20:349. [PMID: 33081717 DOI: 10.1186/s12876-020-01502-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
576 Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol 2016;111:658-64. [PMID: 27002796 DOI: 10.1038/ajg.2016.57] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
577 Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919-928. [PMID: 26651253 DOI: 10.1016/j.bpg.2015.09.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
578 Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. F1000Res 2017;6:1630. [PMID: 29093809 DOI: 10.12688/f1000research.12417.2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
579 Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284-91. [PMID: 33746083 DOI: 10.1016/j.jhep.2021.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
580 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
581 Lin K, Huang Q, Huo Y, Zeng J, Ding Z, Guo P, Chen Z, Zeng Y, Liu J. Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma. Cancer Manag Res 2020;12:7771-81. [PMID: 32943923 DOI: 10.2147/CMAR.S257016] [Reference Citation Analysis]
582 Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, Chu J, El-Serag HB. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018;155:1828-1837.e2. [PMID: 30144434 DOI: 10.1053/j.gastro.2018.08.024] [Cited by in Crossref: 176] [Cited by in F6Publishing: 178] [Article Influence: 44.0] [Reference Citation Analysis]
583 Einer C, Leitzinger C, Lichtmannegger J, Eberhagen C, Rieder T, Borchard S, Wimmer R, Denk G, Popper B, Neff F, Polishchuk EV, Polishchuk RS, Hauck SM, von Toerne C, Müller JC, Karst U, Baral BS, DiSpirito AA, Kremer AE, Semrau J, Weiss KH, Hohenester S, Zischka H. A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats. Cell Mol Gastroenterol Hepatol 2019;7:571-96. [PMID: 30586623 DOI: 10.1016/j.jcmgh.2018.12.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
584 Salomone F, Li Volti G, Rosso C, Grosso G, Bugianesi E. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis: Unconjugated bilirubin and steatohepatitis. J Gastroenterol Hepatol 2013;28:1202-8. [DOI: 10.1111/jgh.12155] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
585 Halaoui AF, Ali AH, Habib SG, Kanso M, Daniel F, Mukherji DM, Khalife MJ, Jaafar RF, Faraj W. Gender differences in liver fibrosis among patients younger than 50 years: A retrospective cohort study. Clin Res Hepatol Gastroenterol 2020;44:733-8. [PMID: 32169461 DOI: 10.1016/j.clinre.2020.01.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
586 Cairoli V, De Matteo E, Rios D, Lezama C, Galoppo M, Casciato P, Mullen E, Giadans C, Bertot G, Preciado MV, Valva P. Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. Sci Rep 2021;11:5129. [PMID: 33664397 DOI: 10.1038/s41598-021-84674-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
587 Chung GE, Kim D, Kwak MS, Yang JI, Yim JY, Lim SH, Itani M. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol 2016;22:146-51. [PMID: 27044765 DOI: 10.3350/cmh.2016.22.1.146] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
588 Ge P, Yang H, Lu J, Liao W, Du S, Xu Y, Xu H, Zhao H, Lu X, Sang X, Zhong S, Huang J, Mao Y. Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage. Gastroenterol Res Pract 2016;2016:5120760. [PMID: 28101103 DOI: 10.1155/2016/5120760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
589 Elangovan H, Rajagopaul S, Williams SM, McKillen B, Britton L, McPhail SM, Horsfall LU, Valery PC, Hayward KL, Powell EE. Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. Hepatol Commun 2020;4:518-26. [PMID: 32258947 DOI: 10.1002/hep4.1486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
590 Navaratna R, Zhao R, Colgan TJ, Hu HH, Bydder M, Yokoo T, Bashir MR, Middleton MS, Serai SD, Malyarenko D, Chenevert T, Smith M, Henderson W, Hamilton G, Shu Y, Sirlin CB, Tkach JA, Trout AT, Brittain JH, Hernando D, Reeder SB; RSNA Quantitative Imaging Biomarker Alliance - Proton Density Fat Fraction Biomarker Committee. Temperature-corrected proton density fat fraction estimation using chemical shift-encoded MRI in phantoms. Magn Reson Med 2021;86:69-81. [PMID: 33565112 DOI: 10.1002/mrm.28669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
591 Imai Y, Yoshida O, Watanabe T, Yukimoto A, Koizumi Y, Ikeda Y, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation. PLoS One 2019;14:e0212589. [PMID: 30794626 DOI: 10.1371/journal.pone.0212589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
592 Gesnik M, Bhatt M, Roy Cardinal MH, Destrempes F, Allard L, Nguyen BN, Alquier T, Giroux JF, Tang A, Cloutier G. In vivo Ultrafast Quantitative Ultrasound and Shear Wave Elastography Imaging on Farm-Raised Duck Livers during Force Feeding. Ultrasound Med Biol 2020;46:1715-26. [PMID: 32381381 DOI: 10.1016/j.ultrasmedbio.2020.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
593 Palmer M. Nonalcoholic Fatty Liver Disease. In: Mullin GE, Cheskin LJ, Matarese LE, editors. Integrative Weight Management. New York: Springer; 2014. pp. 145-69. [DOI: 10.1007/978-1-4939-0548-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
594 Yilmaz Y, Eren F. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2014;26:1292-5. [DOI: 10.1097/meg.0000000000000184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
595 Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014;63:207-17. [DOI: 10.1016/j.metabol.2013.09.013] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 16.1] [Reference Citation Analysis]
596 Taskinen MR, Packard CJ, Borén J. Dietary Fructose and the Metabolic Syndrome. Nutrients 2019;11:E1987. [PMID: 31443567 DOI: 10.3390/nu11091987] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 18.7] [Reference Citation Analysis]
597 Brady CW. Liver Disease in Pregnancy: What's New. Hepatol Commun 2020;4:145-56. [PMID: 32025601 DOI: 10.1002/hep4.1470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
598 Tovoli F, Ferri S, Piscaglia F. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3909-14. [PMID: 32348210 DOI: 10.2174/1381612826666200429093648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 d'Angelo M, Castelli V, Tupone MG, Catanesi M, Antonosante A, Dominguez-Benot R, Ippoliti R, Cimini AM, Benedetti E. Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. Int J Mol Sci 2019;20:E5422. [PMID: 31683535 DOI: 10.3390/ijms20215422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
600 Smart NA, King N, McFarlane JR, Graham PL, Dieberg G. Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis. Br J Sports Med 2018;52:834-43. [PMID: 27317790 DOI: 10.1136/bjsports-2016-096197] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
601 An X, Yang Z, An Z. MiR-149 Compromises the Reactions of Liver Cells to Fatty Acid via its Polymorphism and Increases Non-Alcoholic Fatty Liver Disease (NAFLD) Risk by Targeting Methylene Tetrahydrofolate Reductase (MTHFR). Med Sci Monit 2017;23:2299-307. [PMID: 28507283 DOI: 10.12659/msm.901377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
602 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
603 Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int 2015;35:2129-38. [PMID: 25646700 DOI: 10.1111/liv.12794] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
604 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
605 Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41:368-378. [PMID: 25496369 DOI: 10.1111/apt.13052] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
606 Lao TT. Implications of abnormal liver function in pregnancy and non-alcoholic fatty liver disease. Best Pract Res Clin Obstet Gynaecol 2020;68:2-11. [PMID: 32312689 DOI: 10.1016/j.bpobgyn.2020.02.011] [Reference Citation Analysis]
607 Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, Nakatani T, Kikuchi E, Moriyasu H, Matsumoto M. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep. 2016;4:183-187. [PMID: 26893835 DOI: 10.3892/br.2016.569] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
608 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
609 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
610 Bozic MA, Subbarao G, Molleston JP. Pediatric Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2013;28:448-58. [DOI: 10.1177/0884533613489153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
611 Balakrishnan M, El-Serag HB, Kanwal F, Thrift AP. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci 2017;62:526-33. [PMID: 27995401 DOI: 10.1007/s10620-016-4401-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
612 Kahramanoğlu Aksoy E, Göktaş Z, Albuz Ö, Akpınar MY, Öztürk D, Buluş H, Uzman M. Effects of sleeve gastrectomy on liver enzymes, non-alcoholic fatty liver disease-related fibrosis and steatosis scores in morbidly obese patients: first year follow-up. Journal of Laboratory Medicine 2019;43:115-22. [DOI: 10.1515/labmed-2018-0181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
613 Chung GE, Yim JY, Kim D, Kwak M, Yang JI, Chung SJ, Yang SY, Kim JS. Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. Digestive and Liver Disease 2017;49:57-62. [DOI: 10.1016/j.dld.2016.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
614 Schwenger KJP, Ghorbani Y, Li C, Fischer SE, Jackson TD, Okrainec A, Allard JP. Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. OBES SURG 2020;30:2572-8. [DOI: 10.1007/s11695-020-04514-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
615 Omolekulo TE, Michael OS, Olatunji LA. Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid. Biomed Pharmacother 2019;110:869-77. [PMID: 30557836 DOI: 10.1016/j.biopha.2018.12.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
616 Jia W, Rajani C. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. Adv Exp Med Biol 2018;1061:95-110. [PMID: 29956209 DOI: 10.1007/978-981-10-8684-7_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
617 Fingas CD, Best J, Sowa J-P, Canbay A. Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clinical Liver Disease. 2016;8:119-122. [PMID: 31041078 DOI: 10.1002/cld.585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
618 Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE. Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. Cell Death Differ 2015;22:1985-94. [PMID: 25909884 DOI: 10.1038/cdd.2015.46] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
619 Ye JZ, Zhong BH. Landmarks in research of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2017; 25(35): 3094-3103 [DOI: 10.11569/wcjd.v25.i35.3094] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
620 Wang X, Seo YA, Park SK. Serum selenium and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011-2016. Environ Res 2021;197:111190. [PMID: 33872646 DOI: 10.1016/j.envres.2021.111190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
621 González-Terán B, Matesanz N, Nikolic I, Verdugo MA, Sreeramkumar V, Hernández-Cosido L, Mora A, Crainiciuc G, Sáiz ML, Bernardo E, Leiva-Vega L, Rodríguez E, Bondía V, Torres JL, Perez-Sieira S, Ortega L, Cuenda A, Sanchez-Madrid F, Nogueiras R, Hidalgo A, Marcos M, Sabio G. p38γ and p38δ reprogram liver metabolism by modulating neutrophil infiltration. EMBO J 2016;35:536-52. [PMID: 26843485 DOI: 10.15252/embj.201591857] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
622 Zelber-sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Translational Research 2015;165:428-36. [DOI: 10.1016/j.trsl.2014.10.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
623 Yang J, Wei Q, Peng X, Peng X, Yuan J, Hu D. Relationship between Methyl Tertiary Butyl Ether Exposure and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Petrol Station Attendants in Southern China. Int J Environ Res Public Health 2016;13:E946. [PMID: 27669281 DOI: 10.3390/ijerph13100946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
624 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 25.0] [Reference Citation Analysis]
625 Kwak M, Yim JY, Yi A, Chung G, Yang JI, Kim D, Kim JS, Noh D. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Digestive and Liver Disease 2019;51:1030-5. [DOI: 10.1016/j.dld.2018.12.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
626 Chung GE, Lee Y, Yim JY, Choe EK, Kwak MS, Yang JI, Park B, Lee JE, Kim JA, Kim JS. Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. Gut Liver. 2018;12:316-323. [PMID: 29271184 DOI: 10.5009/gnl17306] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
627 Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar A. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016;30:1540-1548. [PMID: 27270872 DOI: 10.1002/ptr.5659] [Cited by in Crossref: 194] [Cited by in F6Publishing: 181] [Article Influence: 32.3] [Reference Citation Analysis]
628 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
629 Reilly NR, Lebwohl B, Hultcrantz R, Green PH, Ludvigsson JF. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol. 2015;62:1405-1411. [PMID: 25617505 DOI: 10.1016/j.jhep.2015.01.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
630 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
631 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
632 Zhang XQ, Xu CF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1768-1776 [PMID: 24587654 DOI: 10.3748/wjg.v20.i7.1768] [Cited by in CrossRef: 145] [Cited by in F6Publishing: 135] [Article Influence: 18.1] [Reference Citation Analysis]
633 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
634 Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut. 2016;65:1546-1554. [PMID: 26002934 DOI: 10.1136/gutjnl-2015-309456] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
635 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 350] [Article Influence: 45.6] [Reference Citation Analysis]
636 Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72:816-827. [PMID: 31887369 DOI: 10.1016/j.jhep.2019.11.024] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
637 Lim SL, Johal J, Ong KW, Han CY, Chan YH, Lee YM, Loo WM. Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial. JMIR Mhealth Uhealth 2020;8:e14802. [PMID: 32281943 DOI: 10.2196/14802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
638 Chalasani N, Vuppalanchi R, Rinella M, Middleton MS, Siddiqui MS, Barritt AS 4th, Kolterman O, Flores O, Alonso C, Iruarrizaga-Lejarreta M, Gil-Redondo R, Sirlin CB, Zemel MB. Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:1639-1651. [PMID: 29696666 DOI: 10.1111/apt.14674] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
639 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018; 10(12): 956-965 [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
640 Yang Y, Pham TX, Wegner CJ, Kim B, Ku CS, Park YK, Lee JY. Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice. Br J Nutr 2014;112:1797-804. [PMID: 25328157 DOI: 10.1017/S0007114514002554] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
641 Kobayashi Y, Tatsumi H, Hattori M, Sugiyama H, Wada S, Kuwahata M, Tanaka S, Kanemasa K, Sumida Y, Naito Y, Fukui M, Kido Y. Comparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Biochem Nutr 2016;59:215-9. [PMID: 27895389 DOI: 10.3164/jcbn.16-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
642 Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. Contemp Clin Trials 2020;89:105922. [PMID: 31881392 DOI: 10.1016/j.cct.2019.105922] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
643 Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, Rolston D, Chu X, Argyropoulos G, Ibele A, Gerhard GS. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg 2015;25:2368-75. [PMID: 26003548 DOI: 10.1007/s11695-015-1707-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
644 Usman M, Bakhtawar N. Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. Cureus 2020;12:e9018. [PMID: 32775098 DOI: 10.7759/cureus.9018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
645 Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal 2018;49:105-15. [PMID: 29902522 DOI: 10.1016/j.cellsig.2018.06.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
646 Jiang ZG, de Boer IH, Mackey RH, Jensen MK, Lai M, Robson SC, Tracy R, Kuller LH, Mukamal KJ. Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: The Cardiovascular Health Study. Metabolism 2016;65:92-9. [PMID: 26892520 DOI: 10.1016/j.metabol.2015.10.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
647 Fujimoto M, Tsuneyama K, Nakanishi Y, Salunga TL, Nomoto K, Sasaki Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Shimada Y, Gershwin ME, Selmi C. A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. J Med Food 2014;17:374-83. [PMID: 24588719 DOI: 10.1089/jmf.2012.0029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
648 Lu ML, Huang H, Liu LM, Chang J. The Relationship between Intestinal Motility and Interstitial Cells of Cajal in Nonalcoholic Fatty Liver Mice. Hepat Mon 2013;13:e13674. [PMID: 24348640 DOI: 10.5812/hepatmon.13674] [Reference Citation Analysis]
649 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 18.1] [Reference Citation Analysis]
650 Takeuchi K, Yokouchi C, Goto H, Umehara K, Yamada H, Ishii Y. Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition. Biochemical and Biophysical Research Communications 2018;507:203-10. [DOI: 10.1016/j.bbrc.2018.11.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
651 Machado MV, Kruger L, Jewell ML, Michelotti GA, Pereira Tde A, Xie G, Moylan CA, Diehl AM. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. Dig Dis Sci. 2016;61:137-148. [PMID: 26403427 DOI: 10.1007/s10620-015-3871-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
652 Hanamatsu H, Ohnishi S, Sakai S, Yuyama K, Mitsutake S, Takeda H, Hashino S, Igarashi Y. Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr Diabetes 2014;4:e141. [PMID: 25329603 DOI: 10.1038/nutd.2014.38] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 10.3] [Reference Citation Analysis]
653 Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis. 2012;13:153-160. [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
654 Ansari S, Haboubi H, Haboubi N. Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab 2020;11:2042018820934955. [PMID: 32612803 DOI: 10.1177/2042018820934955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
655 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
656 Cannito S, Morello E, Bocca C, Foglia B, Benetti E, Novo E, Chiazza F, Rogazzo M, Fantozzi R, Povero D. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS One. 2017;12:e0172575. [PMID: 28249038 DOI: 10.1371/journal.pone.0172575] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
657 Lee SB, Park BJ, Lee YJ, Jung DH. Early Chronic Kidney Disease (G1-G3a) in Combination with Steatosis as a Predictor of Incident Ischemic Heart Disease: A Longitudinal Study in Non-Diabetic Koreans. Biomedicines 2021;9:1358. [PMID: 34680475 DOI: 10.3390/biomedicines9101358] [Reference Citation Analysis]
658 Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016;65:1006-1016. [PMID: 27312947 DOI: 10.1016/j.jhep.2016.06.005] [Cited by in Crossref: 176] [Cited by in F6Publishing: 162] [Article Influence: 29.3] [Reference Citation Analysis]
659 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Reference Citation Analysis]
660 Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012;36:345-352. [PMID: 22730920 DOI: 10.1111/j.1365-2036.2012.05196.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
661 Li MH, Chen W, Wang LL, Sun JL, Zhou L, Shi YC, Wang CH, Zhong BH, Shi WG, Guo ZW. RLA8—A New and Highly Effective Quadruple PPAR- α / γ / δ and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis. J Pharmacol Exp Ther 2019;369:67-77. [DOI: 10.1124/jpet.118.255216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
662 Weinstein G, Zelber-Sagi S, Preis SR, Beiser AS, DeCarli C, Speliotes EK, Satizabal CL, Vasan RS, Seshadri S. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study. JAMA Neurol. 2018;75:97-104. [PMID: 29159396 DOI: 10.1001/jamaneurol.2017.3229] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
663 Kühn JP, Meffert P, Heske C, Kromrey ML, Schmidt CO, Mensel B, Völzke H, Lerch MM, Hernando D, Mayerle J, Reeder SB. Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. Radiology 2017;284:706-16. [PMID: 28481195 DOI: 10.1148/radiol.2017161228] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
664 Roerecke M, Nanau R, Rehm J, Neuman M. Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. EBioMedicine. 2016;8:317-330. [PMID: 27428441 DOI: 10.1016/j.ebiom.2016.04.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
665 Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31:1621-1632. [PMID: 28398960 DOI: 10.1097/qad.0000000000001504] [Cited by in Crossref: 79] [Cited by in F6Publishing: 32] [Article Influence: 19.8] [Reference Citation Analysis]
666 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
667 Narayanan M, Gopi A, Natarajan D, Kandasamy S, Saravanan M, El Askary A, Elfasakhany A, Pugazhendhi A. Hepato and nephroprotective activity of methanol extract of Hygrophila spinosa and its antibacterial potential against multidrug resistant Pandoraea sputorum. Environ Res 2021;201:111594. [PMID: 34186080 DOI: 10.1016/j.envres.2021.111594] [Reference Citation Analysis]
668 Kučera O, Endlicher R, Roušar T, Lotková H, Garnol T, Drahota Z, Cervinková Z. The effect of tert-butyl hydroperoxide-induced oxidative stress on lean and steatotic rat hepatocytes in vitro. Oxid Med Cell Longev 2014;2014:752506. [PMID: 24847414 DOI: 10.1155/2014/752506] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
669 Boemeke L, Raimundo FV, Bopp M, Leonhardt LR, Fernandes SA, Marroni CA. The correlation of neck circumference and insulin resistance in NAFLD patients. Arq Gastroenterol. 2019;56:28-33. [PMID: 31141077 DOI: 10.1590/s0004-2803.201900000-06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
670 Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
671 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
672 Lee E, Lim Y, Kwon SW, Kwon O. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. The Journal of Nutritional Biochemistry 2019;68:33-41. [DOI: 10.1016/j.jnutbio.2019.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
673 Patel NS, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:630-9. [PMID: 23383649 DOI: 10.1111/apt.12237] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
674 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 203] [Article Influence: 24.8] [Reference Citation Analysis]
675 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1902] [Article Influence: 205.7] [Reference Citation Analysis]
676 Edula RG, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P, Pyrsopoulos NT. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol 2018;6:241-6. [PMID: 30271734 DOI: 10.14218/JCTH.2017.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
677 Ahn SH, Yang ES, Cho HR, Lee SO, Ha KT, Kim K. Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. Integr Med Res 2020;9:100422. [PMID: 32489856 DOI: 10.1016/j.imr.2020.100422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
678 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
679 Kamal S, Aldossari KK, Ghoraba D, Abdelhakam SM, Kamal AH, Bedewi M, Nabegh L, Bahnasy K, Hafez T. Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Open Gastroenterol 2018;5:e000150. [PMID: 29503733 DOI: 10.1136/bmjgast-2017-000150] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
680 Karatzas T, Sikalias N, Mantas D, Papalois A, Alexiou K, Mountzalia L, Kouraklis G. Histopathological changes and onset of severe hepatic steatosis in rats fed a choline-free diet. Exp Ther Med 2018;16:1735-42. [PMID: 30186395 DOI: 10.3892/etm.2018.6385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
681 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
682 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
683 Lopez AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, Rehm J, Volkow ND, Koob G, Ferri CP. Remembering the forgotten non-communicable diseases. BMC Med 2014;12:200. [PMID: 25604462 DOI: 10.1186/s12916-014-0200-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
684 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
685 Schwenger KJP, Fischer SE, Jackson TD, Okrainec A, Allard JP. Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet. OBES SURG 2018;28:1109-16. [DOI: 10.1007/s11695-017-2980-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]